Vol.8 No 4 | July-August 2016 | New Delhi
NEW! Medical DEVICES
Upcoming.....
Telemedicines PREVENTS DEATH & HOSPITAL STAYS
Held Alongside
Incorporating
Organised by
Worldwide Associate Tel : +65 6233 6638 Fax : +65 6233 6633 Email : mta@sesallworld.com
MTA17Ad_MDA_W21x28cm_D1.indd 1
Endorsed
Supported by
Held in
Tel : +44 207 840 2134 Fax : +44 207 840 2119 Email : mta@oesallworld.com
27/7/16 5:24 PM
e
d
i
t
o
r
i
a
l
h i g h l i g h t s
Vol.8 No.4 | July-August 2016 | Annual Suscription: Rs.2,000 | Overseas: US$250
4 British company launches full range of pioneering pressure mattress solutions in India 6 MEDICAL MANUFACTURING ASIA 2016 10 Medical Fair ASIA - Concurrent Conferences and Seminars 14 Frost & Sullivan Announces the Launch of 2016 India Healthcare Excellence Awards 16 STARLED1 EVO - MEDICAL LAMP 20 Managed Equipment Services contract from UK worth around €50 million 24 CPhI Istanbul hosts government and industryto strengthen Turkey as MENA pharma hub 26 Top Medical Technology Companies 27 MEDICAL FAIR ASIA introduces inaugural sports medicine conference 28 10th COMPAMED Spring Convention 34 MEDICA 2016 + COMPAMED 2016: 39 INTELSIUS EXTENDS ITS ORCA RANGE FOR THE TRANSPORT OF WHOLE BLOOD PRODUCTS 42 Godrej Appliances to Contribute Towards 30% Reduction in Global Vaccine Wastage 45 Curofy builds its own Medical device marketplace 47 EHIC in the Wake of Brexit: What’s Next for UK Travellers and Expats? 50 Latest Medical Devices 2016
Zika virus emergency among topics to be addressed at MEDICAL FAIR ASIA’s inaugural disaster and military medicine conference The inaugural DiMiMED Asia, the conference on Disaster and Military Medicine will be held on the 31st of August, co-located with MEDICAL FAIR ASIA (MFA), the region’s premier medical trade fair. The conference organiser Messe Düsseldorf Asia (MDA) has been staging previous iterations of DiMiMED Asia at MEDICA, the world’s largest medical trade fair based in Dusseldorf, Germany. MFA will take place from the 31st August to the 2nd of September at The Sands Expo & Convention Centre at Marina Bay Sands in Singapore.
subject-orientated involvement of our industrial partners helps raise awareness among participants of further opportunities for cooperation. Among the many issues, the conference will focus on are Disaster Management on Land and Sea, Traumatology and Air Evacuation as well as Infectious Diseases and Force Health Protection.
S
Some of the highlights of the conference include:
ince its inception three years ago, DiMiMED has grown into an internationally recognised conference focusing on current issues in military medicine and disaster medicine. The number and variety of disasters taking place all over the world have shown that it is absolutely essential for civilian and military medical services to join forces to provide optimum on-site medical care during and in the aftermath of emergency situations. With civilian medical services and the medical services of armed forces increasingly being called upon to work together to deal with disasters, DiMiMED provides a much-needed platform that promotes global cooperation by bringing together civilian and military experts from around the world to share experiences, hold discussions and build contacts. The
Traumatology & Air Evacuation 1. Advances and Developments in Aeromedical Evacuation by Major Dr Norman Tan Zhi Peng 2. Satcom-based Telemedicine for Challenging Missions by Dr Mario Polaschegg
Disaster Management on Land & Sea 1. Medical Aspects of Radiation by Prof Aleksander Grebenyuk 2. Organisational Experiences on Medical Management by Colonel Mehmet Eryilmaz 3. Nepal Earthquake 2015: Medical Issues and Challenges by MG Dr Kishore Rana
Infectious Diseases and Force Health Protection 1. Dengue Virus: Which Prevention for Troops? By Colonel Dr Benjamin Queyriaux 2. Zika Virus: A New Emergency by Colonel Dr Benjamin Queyriaux 3. Ebola Prevention, Control Strategy, Pattern of Chinese Army by Professor Zhao Jingming For further information, or to register, please visit: www.medicalfair-asia. com
Medical Device ASIA | July-August 2016 | 3
British company launches full range of pioneering pressure mattress solutions in India
The company has focused on four key areas - microclimate control, patient safety and comfort, maximising infection control and offering additional nursing support.
B
ritish company, Rober will soon launch to the Indian market an innovative range of pressure mattresses that cater for immobile, critically ill and bariatric patients. Over the last few years, UKbased, Rober has invested heavily in R&D to develop a complete range of pressure ulcer mattresses that can be used in everyday nursing environments, as well as acute care facilities. The innovative range of mattresses and overlays has been developed in conjunction with clinicians, and includes solutions and features clinically proven technology that prevents pressure injuries from developing. The technology
also has therapeutic properties that promote the healing of established ulcers. This new generation of mattresses are fully automatic, and patients nursed upon them require less frequent manual repositioning, thus relieving the pressure on busy nursing staff. Designed to mechanically replicate the body’s natural spontaneous movement in response to unrelieved pressure, the mattresses provide regular and complete pressure elimination to all parts of the body in contact with the mattress.
4 | July-August 2016 | Medical Device ASIA
Additional features such as a touch screen visual display panel, comfort settings, timed static mode, audible and visual alarms, permanently inflated side formers, maximum inflation mode, and simplicity of decontamination for effective infection control provide benefits to both patients and busy nursing staff. Included within the new product ranges are two different mattress types - the premium NoDec® range and a secondary ‘cost effective’ range of
mattress solutions, AirFlex, which have been designed to fulfil the requirements of ‘affordable healthcare’. Mike Hutson, Chief Executive of Rober, said: “We have been working closely with our partners in India and we are delighted to be able to launch our new range of mattresses here. All of our technologies have been designed to offer maximum flexibility to patients who are at risk of pressure damage. They are effective and proven solutions in the prevention and treatment of pressure ulcers and we are looking forward to ‘stopping the pressure’ across India.”
14 – 17 NOVEMBER 2016 DÜSSELDORF GERMANY www.medica-tradefair.com
WORLD FORUM FOR MEDICINE Every year in November MEDICA provides an exceptional experience for experts from around the world. The World Forum for Medicine presents a broad product spectrum from some 5,000 exhibitors. Take advantage of MEDICA and its special products for your area of expertise, too.
BE PART OF IT!
Messe Duesseldorf India Pvt.Ltd. Centre Point 7th. Floor Junction of S.V. Road & Juhu Tara Road, Santacruz West Mumbai 400 054 Tel. (0091 22) 6678 99 33 _ Fax (0091 22) 6678 99 11 messeduesseldorf@md-india.com
Medical Device ASIA | July-August 2016 | 5
Key exhibitors and industry partners show strong support for
MEDICAL MANUFACTURING ASIA 2016 3rd Manufacturing Processes for Medical Technology Exhibition and Conference sets the stage as the industry’s knowledge-information exchange platform
E
Established as Asia’s leading exhibition for the medical technology, medical manufacturing processes and related sectors, MEDICAL MANUFACTURING ASIA 2016 – modelled after COMPAMED and jointly organised by SPETA (Singapore Precision Engineering and Technology Association) and Messe Düsseldorf Asia, will bring to the industry the latest advances and an extensive product range from 200 exhibitors across 20 countries. This includes strong representation from national/ country groups from Austria, China, Germany, Italy, Japan, Taiwan, USA and Europe – a group presence led by the IVAM Microtechnology Network. 6 | July-August 2016 | Medical Device ASIA
xhibiting names include, BRUKER SINGAPORE, P3 SRL, RESILIA SRL, HI-TECH MEDICAL, MICRO SYSTEMS TECHNOLOGIES, QOSINA, TOTEX INTERNATIONAL, R + E AUTOMATIONSTECHNIK GMBH, VASCUTEK, STARLIM SPRITZGUSS GMBH, SUNNINGDALE TECH, NIHON DENTO KOUGYO, KAMADA SPRING, ALC TECHNOLOGIES, ALEX CORPORATION, ABRASIVE ENGINEERING, FORMATIVE TECH, LUMBERG ASIA PACIFIC, KIEFEL GMBH, NANOFILM TECHNOLOGIES INTERNATIONAL, PACIFIC ADHESIVE SYSTEMS, RACER TECHNOLOGY, SP MANUFACTURING, VASCUTEK and many more. With the MedTech sectors operating within a highly regulated framework with unique research, design, development and manufacturing considerations, MEDICAL MANUFACTURING ASIA 2016 features a line-up of new materials, substances and components covering MedTech’s upstream and downstream processes. The specialist trade fair will present a converging, knowledge-information exchange platform for the industry and will be staged over three days as it plays host to a series of concurrent events for industry specialists
to gain MedTech insights to the latest developments and best practices across various fields and specialities. Alongside the exhibition, a series of thought leading sessions by leading experts covering various topics will be addressed at MEDICAL MANUFACTURING ASIA 2016 including:
MEDTECH BUSINESS FORUM • Jointly organised by Singapore Institute of Manufacturing Technology (SIMTech) and Messe Düsseldorf Asia • The forum will gather the MedTech industry to review trends in the Asian, European and American markets; to examine how future needs can be addressed • Speakers at the forum include, Mr Steven Koh, Advisor, SPETA, Mr Philip Tay, Research Analyst, Transformational Health, Frost & Sullivan, Mr Abhay B. Bangi, Partner, Transaction Advisory Services, Ernst & Young and Mr John Lim, Lead, MedTech Initiative, Precision Engineering Centre of Innovation (PE COI), SIMTech IVAM FORUM – HIGH-TECH FOR MEDICAL DEVICES • Organised by IVAM
Microtechnology Network, the session will be chaired by Dr. Thomas R. Dietrich, the network’s CEO • Learn from successful case studies from the likes of Microsystems UK, Specialty Coating Systems, Finetech and Z Microsystems • Topics covered to include micro moulding for today’s medical devices, advanced conformal coating technologies for the medical industry, challenges of sensor packaging for medical imaging applications and digitalization in healthcare and disease
To have visitors make the most of their visit to MEDICAL MANUFACTURING ASIA 2016, networking opportunities with some 7,000 new and potential suppliers, customers and business partners from the region will be made more targeted with a complimentary business matching service, available preand during the exhibition. For space bookings and visitor registration to MMA 2016, please visit www.medmanufacturing-asia.com. For more information on MFA 2016, please visit http://www.medicalfair-asia.com
MEDTECH SME WORKSHOP • Organised by APACMed, the workshop will focus on product design & development, IP management, regulatory strategy, clinical trial management, capitalraising, commercialization and distribution/channel management, which will be of deeper relevance to research institutes, start-ups and smaller MedTech R&D or manufacturing businesses Re-enforcing the merits of the co-location with MEDICAL FAIR ASIA (MFA) 2016 – the region’s No. 1 exhibition for the Hospital, Diagnostic, Pharmaceutical, Medical & Rehabilitation Equipment & Supplies sectors, MEDICAL MANUFACTURING ASIA (MMA) 2016 is well poised to be the gateway for those in the MedTech sectors to reach out to a ready pool and highly targeted audience – through MFA’s exhibitor participation of 1,000 companies from 45 countries and some 15,000 visitors. The synergistic trade fairs in their respective disciplines will also provide an under-one roof experience, represented by the diversified and expansive showing of the latest products, technology and solutions tailored for Asia’s medical and healthcare industry, and an ideal business platform to source, exchange expertise and establish knowledge links, in capturing a bigger market share in the healthcare and MedTech sectors. Medical Device ASIA | July-August 2016 | 7
Japan: Shiko +81 90 8051 5394
shiko.iwai@gardnerdenver.com | China: Mark +86-135-0170-935
eddie.lee@gardnerdenver.com
michelle.wu@gardnerdenver.com mark.lou@gardnerdenver.com
keri.mcneill@gardnerdenver.com | Korea: Eddie +82 10 7720 2584
manoj.ahire@gardnerdenver.com | SE Asia: Michelle +852 9170 0693
Australia: Keri +61 (0) 402 275 962
India: Manoj +91 9004282345
B/404, 4th Floor , Kedarnath, opp. Gokulanand Hotel,Western Express Highway, Dahisar (E) Mumbai – 400 068. T: +91 22 658 12345 | F: +91 22 289 20224
Gardner Denver Engineered Products India Pvt. Ltd
Frost & Sullivan Announces the Launch of 2016 India Healthcare Excellence Awards
to Recognize Enterprises for their Commitment to Healthcare in India Nominations are open for enterprises to participate in this awards platform until 15th August 2016 Frost & Sullivan is proud to announce the launch of its 8th Annual India Healthcare Excellence Awards 2016. The yearly event, converging the frontrunners of the country’s healthcare industry, will be held on 21st October, 2016 at The Westin, Gurgaon. The program, showcasing the best practices and implementation of innovative strategies, will recognize companies that are transforming the Indian healthcare system while striving towards excellence in practices and operations. Nominations are open for the 8th Annual India Healthcare Excellence Awards and will close by 15th August 2016. Companies looking to apply for
nominations or interested in knowing more about the award categories and titles can contact Shruti Jadhav, Manager, Best Practice Research, Frost & Sullivan – Middle East, North Africa and South Asia at shruthij@frost.com or +91 20 40778885. For regular updates on the awards banquet, follow our official Twitter hashtag: #FSHCawards or visit www.frost.com/hcawards2016 The Indian healthcare ecosystem is on the verge of a significant transformational shift. With major players as well as innovative start-ups incorporating new strategies, the space is more competitive than ever, necessitating recognition of deserving companies. This awards program is an exceptional platform recognizing enterprises and individuals who have achieved excellence in healthcare practices and their extraordinary efforts which have set new benchmarks for their peer groups and the industry. This year, a new award category has been introduced – Health Insurance. Talking about the same, Mr. Jayant Singh, Director, Transformational Health Practice, Frost & Sullivan – Middle 14 | July-August 2016 | Medical Device ASIA
East, North Africa and South Asia, said, “With the introduction of Health Insurance in our awards program, we will cover an important aspect of healthcare industry in India. Health Insurance is one of the fastest growing and robust segments in the non-life insurance industry in India, and we are glad to recognize and felicitate deserving companies in this segment.” With this new introduction, the award titles will be clustered under five major categories – Special Awards, Pharmaceuticals and Biotechnology, Healthcare Delivery Services, Medical Technologies, and Health Insurance.
The Frost & Sullivan awards system encompasses a meticulous and rigorous analysis of market performance indicators and other criteria of shortlisted companies conducted by senior industry analysts. Their study is subjected to a 10-step process supported by a Decision Support Matrix (DSM). The detailed analysis is also reviewed by a panel of eminent industry experts and top decision makers who finally select the most deserving recipient under each category.
About Frost & Sullivan Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the Global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion For more details, please contact: http://ww2.frost.com Twitter: @Frost_MENASA #FSHCawards
8
th
ANNUAL INDIA HEALTHCARE
Excellence Awards 2016
Nominations Close 15th August, 2016 For More Details, Please Contact Shruti Jadhav, Manager - Best Practice, Frost & Sullivan E: shruthij@frost.com | P: 91 20 40778885
STARLED1 EVO - MEDICAL LAMP
STARLED1 EVO is the single LED lamp manufactured by ACEM Medical Company. It is suitable for several medical specialties: dermatology, general medicine, gynaecology, dentistry. It is a multifunctional and versatile lamp, ideal for diagnostics, cosmetic medicine, first aid and recovery room. It is a reliable product that assures excellent light intensity and low consumption (12W) at the same time. STARLED1 EVO has a functional design, is easy to move and its light head remains steady during its use once positioned. The lamp has a smooth and easy-to-clean surface to allow the best cleanliness. Its light beam is homogeneous and intense with 60.000 lux at 50 cm and producing a color temperature of 4.500 °K and a color rendering index (CRI) of 95.
Technical features Product Class EN 60601-2-41 I Max. light power 60.000 lux @ 50 cm Light adjustment from 0% to 100% Light field diameter (d50) 9 cm @ 50 cm Color temperature 4.500 °K Color rendering index (Ra) 5 LED average life 50.000 hours abt. Voltage 100-240 VAC– 50/60 Hz Low DC voltage version 12 VDC Power consumption 12W Light head diameter 12 cm Light head and arm weight 1 kg Trolley weight 3 kg Painting White RAL 9002
The innovative I–SENSE® touch panel allows to adjust light intensity and select the desired light level according to the different needs. STARLED1 EVO is available with articulated or flexible arm and according to its final use can be provided with wall, rail and table clamp or be configured as ceiling or adjustable height trolley version. 16 | July-August 2016 | Medical Device ASIA
ACEM SpA, Medical Company Division, Via della Tecnica 29 - 40050 Argelato, Bologna – ITALY Ph +39 051 721844 Fax +39 051 721855, Email: info@acem.it | Website:www.acem.it
ADVATE Now Available in India for the Treatment and Prophylaxis of Hemophilia A • • •
ADVATE is the world’s most widely used FVIII treatment with 13 years of proven real-world patient experience World’s first third generation clotting factor eliminates the risk of transmission of blood-borne pathogens Every bleed matters – In India today, there are about 16,000 patients registered with Hemophilia but the actual number could be 7 times more due to low awareness, diagnosis and treatment
S
hire plc (LSE: SHP, NASDAQ: SHPG) announces the launch of ADVATE (Octocog alfa Recombinant Coagulation Factor VIII) in India for the treatment and prophylaxis of bleeding in patients with hemophilia A. ADVATE, which came to Shire as part of the recent Baxalta combination, was approved in the U.S. since July 2003 and has a proven safety and efficacy profile with over 13 years of real-world patient experience data. It is the world’s most widely used FVIII treatment to date. Marketing Authorization Holder: Baxalta Biosciences India Pvt. Ltd. (now part of Shire), 6th Floor, Tower-C, Building No.8, DLF Cyber City, DLF Phase-II, Gurgaon-122 002, Haryana, India.
ADVATE is the world’s first third generation recombinant factor VIII – a full-length molecule that uses the complete gene, similar to the factor VIII that occurs naturally in the body, and was first of its kind to be developed without the addition of any human or animal-derived protein in the cell culture process, purification or final formulation. The treatment of this rare genetic bleeding disease, Hemophilia, also greatly reduce the risk of transmission of blood-borne pathogens, and relies on clotting factors concentrates of high quality.
“Shire has been part of the Hemophilia community for over 60 years. We are committed to the advancement of Hemophilia treatments and elevating the standard of care for hemophilia patients in India because we know that many of them out there are not diagnosed, let alone treated. Striving toward a goal of zero bleeds, we are able to bring innovative third generation treatments like ADVATE to patients in India and help them achieve better outcomes in managing their bleeding conditions,” said Vineet Singhal, Country Head, Baxalta Biosciences India Pvt. Ltd.
• Recombinant clotting factors the first generation of recombinant products use animal products in the culture medium and had human albumin (a human blood product) added as a stabilizer. Second generation products use animalderived materials in the culture medium but do not have added albumin and instead, use sucrose or other non-human derived material as a stabilizer. Third generation products are produced without the addition of any human or animal-derived protein in the cell culture process, purification or final formulation.
Clotting factor concentrates can be made in two different ways: • Plasma-derived clotting factors - prepared from the plasma of donated human blood.
18 | July-August 2016 | Medical Device ASIA
With the introduction of the third generation clotting factors which have no albumin present at any stage of their preparation, patients in India now have access to a safer and more reliable therapy option. ADVATE has a 24 months shelf life and allows 6 months storage at room temperature within this shelf life period. In addition, ADVATE has been clinically shown to reduce the number of bleeding episodes in adults and children (0-16 years) for up to 98 percent when used regularly (prophylaxis). About Hemophilia A Hemophilia A is a challenging chronic disease affecting 1 in 10.000 male births with no difference in geography and races. If untreated, people with haemophilia will suffer from recurrent bleeding causing pains which lead to disability and even young death. Today, The World Federation of Hemophilia estimates that the disease affects more than 400,000 people worldwide, with an estimated 75 percent of them being undiagnosed and untreated or undertreated globally. According to the Hemophilia Federation of India, only 16,000 or 15 percent of the total Hemophilia population has been currently identified in India and the rest lay undiagnosed – which could be ranging 7 times more than the current registered patients. For people with hemophilia, reducing their bleeding episodes (measured by annual bleed rate (ABR)) may have a significant improvement on long-term outcomes and quality of life. About ADVATE ADVATE [Antihemophilic Factor (Recombinant)] is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A (congenital factor VIII deficiency) for: • • •
Control and prevention of bleeding episodes Perioperative management Routine prophylaxis to prevent or reduce the frequency of bleeding episodes
ADVATE is not indicated for the treatment of von Willebrand disease. ADVATE has a demonstrated efficacy and safety profile for the treatment of hemophilia A. ADVATE is a full-length (derived from the complete FVIII gene) recombinant FVIII product that is processed without any blood-based additives. Because no blood-derived components are added at any stage of the manufacturing process, the potential risk of transmitting pathogens that may be carried in blood-based additives is virtually eliminated. There have been no confirmed reports of transmission of HIV, HBV or HCV with rFVIII treatments. ADVATE is the world’s most prescribed FVIII treatment, currently approved in 68 countries worldwide.
Nayati multi super specialty hospital performs 3 life changing pediatric cardiac surgeries in a week in the region Nayati multi super specialty hospital, today announced successful life changing pediatric cardiac surgeries to treat congenital heart defects among children. In last one week, three unusual pediatric cardiac surgeries were conducted at Nayati hospital for 2 year old, 4 year old and 19 year old boys. pediatric cardiac patients operated at the hospital. He was finally convinced. Multiple phlebotomy was done as he had high hemoglobin levels ( 25g/dl, oxygen saturation of 60%). He was discharged on fifth post operative day.
The first case is of Master Gaurav Saxena, son of Mr. Mohan Babu Saxena, Mathura aged 2 year old boy diagnosed at the age of 4 months in local hospital of Mathura to have multiple holes in the heart. He was referred to a renowned private hospital of Delhi. The patient was not comfortable getting the surgery done in Delhi as he had no means of staying in Delhi for the duration of the surgery. Through some sources, Gaurav’s parents came to know about successful pediatric cardiac surgeries performed at Nayati. Gaurav was examined carefully and parents were counseled regarding the need for surgery. He was admitted on 20th of June, 2016 and operated day after and extubated within three hours of surgery and child is now doing well. The second case is of a 19 year old boy diagnosed to be suffering from congenital heart disease, tetralogy of fallot - blue baby syndrome. He was diagnosed to be suffering from heart disease at the age 5 months when parents noticed bluish discoloration of lips and nail bed. As a child he was restless, could barely walk and had hardly slept for almost 3 years. He was taken to various government and private hospital in Delhi but did not get the confidence. At the age of 16yrs, parents noticed deepening cyanosis and easy fatigability, so decided to get him operated. The child was admitted at AIIMS after waiting for almost 2 years for his turn, however, refused surgery at the last minute. Parents were deeply disheartened. They got to know about Nayati. The child was repeatedly counseled for weeks by the doctors and councilor. He was shown successful postoperative
The third case is of four year old boy Dev Aggrawal who was also diagnosed to be suffering from congenital heart disease, tetralogy of fallot - blue baby syndrome since the age of 1year when his parents noticed odd bluish discoloration of lips n nail bed. His parents took the child to corporate hospital at Jaipur and Fortis Escorts Heart Institute Delhi for treatment but could not afford the surgery and cost for staying in hospital for 10-15days. Hence, the surgery was delayed. After learning about the success stories of pediatric cardiac cases being done at Nayati hospital, they got the confidence that even smaller kids with heart defects can be operated in their own city, Mathura. They met the parents of operated kids especially 8months baby with multiple defects in heart who was operated at our hospital. Dev was admitted and operated the very next day. The child is doing quite well and recuperating. Niira Radia, Chairperson Nayati Healthcare stated, “The health statistics reveal a rise in congenital heart disease among children in the region. Most of such diseases can be prevented through timely intervention. However, only 10 per cent of the affected infants with serious heart disease receive timely intervention. The remaining 90 per cent children do not survive because of late or no diagnosis. It is critical that awareness be created amongst the masses on early diagnosis so that the little ones can lead a healthy happy life. The Nayati team of Cardiac Sciences offers
comprehensive care for patients with cardio vascular disease at an affordable cost.” Dr. Venugopal Ram Rao, Chairman of Nayati Centre for Cardiac Sciences stated “Decades ago, only 15 to 20 percent of babies born with heart defects survived to adulthood. Now, it’s 95 percent. India has the largest burden of heart disease among children with 2 lakh children born every year with congenital heart defects (CHD). In less than 60 days, at Nayati we have done close to 20 Pediatric surgeries ranging from 9 months to 19 years - all complicated and never been performed in the region. Each one of them was unique and challenging. Due to innovations in cardiac surgery, we are able to perform such complex surgeries on patients of all the age groups without much complication.” About Nayati Healthcare & Research Pvt. Ltd.: Nayati is India’s first Multi Super-Specialty healthcare group offering premium tertiary care to Tier-II & Tier-III cities. We offer world class patient care services aided by state-of-the-art medical technology and advanced treatment facilities. Our aim is to provide both cost effective and easily accessible healthcare. About Nayati Multi Super Speciality Hospital, Mathura: Nayati Hospital once operational will be the first hospital in the region to provide integrated, comprehensive and high quality healthcare through our Centres of Excellence. These centres will be supported by advanced Intensive Care units comprising of: MICU, CCU, SICU, NICU and PICU. The upcoming hospital in Mathura will also cater to Vrindavan, Agra, Palwal, Firozabad, Mainpuri, Kasganj, Etawah, Etah, Hathras, Agra and surrounding areas.
Medical Device ASIA | July-August 2016 | 19
Managed Equipment Services contract from UK worth around €50 million • •
Sandwell and West Birmingham Hospitals NHS Trust to partner with Siemens on a comprehensive suite of management equipment services 530 000 Patients in UK’s center will benefit from state-of-the-art imaging systems, improving clinical outcomes and enhancing patient care
Sandwell and West Birmingham Hospitals NHS Trust (the Trust) has awarded Siemens Healthineers a cooperation contract worth around Euros 50 million. The Trust is an integrated care organization which is responsible for the care of 530,000 local people in the midwest of UK. For a contract life-time of 10 years, Siemens will provide four hospital sites with a comprehensive suite of management services and solutions for all of its medical imaging equipment. However the partnership not only includes Managed Equipment Services. As part of the customer’s team Siemens experts will help to optimize processes in the hospitals and design technology roadmaps to provide the most relevant and updated technology at all times. 20 | July-August 2016 | Medical Device ASIA
T
he sites across West Birmingham and Sandwell, including the new Midland Metropolitan Hospital opening in October 2018, are set to transform patient care in the area. Like many healthcare providers in the UK, the Trust is facing key challenges including increasing hospital workload, budgetary pressures and a 10- 15% year-on-year rise in demand for CT and MR imaging. The collaboration with Siemens will help to provide the backing required to tackle these issues and create a first-class clinical environ-
ment. The Managed Equipment Service partnership includes the provision, renewal and maintenance of imaging equipment like computer tomography and magnetic resonance, ultrasound, X-ray and molecular imaging, underpinned by solutions to support operational and clinical efficiency. Within the scope of the contract, Siemens will also offer financing, professional services, room planning, training for clinical users as well as onsite
technical support. The collaboration plans to increase the quality of care as well as improve clinical outcomes for patients and to oversee that the technology available is the best fit at any time. The strong alliance will support the Trust’s 2020 vision to become known as the best integrated care organization in the NHS. “The new Midland Metropolitan Hospital is set to open in 2018 and it is essential that the imaging department is equipped with the right technology to meet our needs to prepare us for the future,” comments Dr Jonathan Benham, Consultant Radiologist at SWBH NHS Trust. “The partnership will enable both staff and patients to benefit from a well-designed clinical environment, reduced downtime and improved patient turnaround times. An investment in modern technology is an investment in our patients, who will benefit from the latest medical imaging techniques greatly.” Tony Waite, Director of Finance at SWBH NHS Trust states, “Securing confidence and greater certainty in our services and financial planning is important; we strive to get the best value for money to ensure the most efficient use of public money. We chose to work with Siemens as the result of a competitive process during which we evaluated quality, safety and financial criteria. The out-
come is a partnership which brings together our collective strengths that will work together to achieve our 2020 vision. Together we are stronger which, most importantly, is of benefit to our patients.” “We are very pleased that we are now expanding our business relationship with the Trust and, in so doing, helping to boost its clinical excellence, operational efficiency, and profitability,” says Matthias Platsch, head of Services at Siemens Healthineers. “This Managed Equipment Services contract will enable the Trust to offer its patients premium care supported by stateof-the-art technology, customized training and workflow optimization solutions from Siemens Healthineers. Together we will tackle the challenges facing healthcare today, and help our partner prepare for the future with efficient hospital operations, sustainable business models and high standards of care.”
Sandwell and West Birmingham Hospitals NHS Trust (SWBH NHS Trust) is an integrated care organization, dedicated to improving the lives of local people, to maintaining an outstanding reputation for teaching and education, and to embedding innovation and research. SWBH NHS Trust employs around 7,500 people and spends around £430m of public money, largely drawn from the local Clinical Commissioning Group. That Group and this Trust is responsible for the care of 530,000 local people from across North-West Birmingham and all the towns within Sandwell. Further information is available at http://www. swbh.nhs.uk . Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world’s largest producers of energyefficient, resource-saving technologies, Siemens is No. 1 in offshore wind turbine construction, a leading supplier of gas and steam turbines for power generation, a major provider of power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. The company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2015, which ended on September 30, 2015, Siemens generated revenue of €75.6 billion and net income of €7.4 billion. At the end of September 2015, the company had around 348,000 employees worldwide. Further information is available on the Internet at www. siemens.com.
Medical Device ASIA | July-August 2016 | 21
“Trust Hospital is for all” says Association of Hospitals A ssociation of Hospitals (AOH) is one of the oldest and trusted associations in healthcare of Mumbai. The member hospital
About Association of Hospital:
of AOH have set up an Indigent Patient Fund where The Trust
The Association of Hospitals has been formed under the Memorandum dated August 6, 1985 and is registered under the Societies Registration Act, 1860. The Association is also registered under Maharashtra Public Trust Act, 1950 as Public Charitable Trust with the office of Charity Commissioner, Maharashtra State.
Hospital annually set aside at least 2% of their annual turnover as they are not receiving any grants or any exemption from government. Through the Indigent Patient Fund we help in availing assistance to the lower section of the society by providing treatment in The Trust Hospital at free or negligible cost. Additionally The Trust Hospital also provides concessions to other penurious patients. These facilities are
provided only to the genuinely needy people who are unable to pay for minor or major treatments for a healthy living. In certain cases AOH member hospitals have invested more than its capacity to provide best healthcare services to the patients from the weaker section of the society. “Medical expenses are witnessing a steep rise in today’s age. It is very difficult for a common man to manage the expenses for sudden medical emergencies. With trust hospitals in the scenario all sections of society are able to receive the same medical services. We cater to weaker section of the society and treat them either free or with concessional cost. The member hospitals of AOH are giving & will continue to give the best medical treatments to improve the overall healthcare sector of India.” said Dr. P.M. Bhujang – President, Association of Hospitals. 22 | July-August 2016 | Medical Device ASIA
Presently there are 52 members of the Association and all of them are Public Charitable Trust Hospitals registered under Maharashtra Public Trust Act, 1950 with the concerned offices of Charity Commissioner, Maharashtra State depending upon the Jurisdiction. The members being not-for-profit charitable hospitals render yeomen service to the public and bear a major share of healthcare service to the people.
Transasia Bio-Medicals launches new fully-automated urine chemistry and sediment analyzer at APPI 2016
Laura XL System aids in automatic recognition of elements
Dr. Nitty Mathews with Mrs. Mala Vazirani
(Retd.) Maj. Gen. G.D. Bakshi with the Transasia
(Hony.) Brig. Dr. Arvind Lal launching Laura XL
Dr. Mahendra Patel addressing the delegates
team
Transasia Bio-Medicals, India’s largest In-Vitro Diagnostic (IVD) company, recently announced that it has launched the Laura XL System at the 3rd APPI (Association of Practicing Pathologists - India) Annual Conference 2016 held between 10th and 12th June 2016, at JW Marriott Juhu, Mumbai. This event was a fine example of APPI’s efforts in providing a platform for the dissemination of knowledge in healthcare practices based on clinical guidelines as well as GLP & GCP. The forum has been growing in popularity due to the relentless efforts of Dr. Suvin Shetty, Secretary of APPI and his team. For the first time-ever, more than 30 workshops were held over a period of two days and attended by 800+ clinical experts!
D
hematology and coagulation, with a complete demonstration of Hb-Vario, Laura XL, XN-L, ECL 412 and EM 200 systems. The workshop had eminent clinicians such as Dr. Mahendra Patel (Consultant Diabetologist, Patel Diabetics Care Centre, Mumbai) and Dr. Anil Kamat (Consultant Hematopathologist, Jupiter Hospital, Mumbai) besides experts in pathology such as Dr. Swati Pai (HOD - Lab Medicine, Manipal Hospital, Bangalore), Dr. Anil Handoo (Sr. Consultant- Hematology & Director Lab Services, BLK Super Speciality Hospital, New Delhi), Dr. Kunal Sehgal (Director - Sehgal Path Lab, Mumbai), Dr. Sitalakshmi (Prof. & Head - Dept. of Clinical Pathology, St. John’s Medical College, Bangalore), Dr. Shalini Goel (Consultant Hematopathologist, Medanta Medicity Hospital, New Delhi), Dr. Nitty Mathews (Asst. Prof. Transfusion Medicine & Immunohematology, CMC Hospital, Vellore) and Dr. Chandrahas Godbole (Consultant Pathologist, Dr. Godbole’s Lab, Pune).
uring the event, (Hony.) Brig. Dr. Arvind Lal, (Padma Shri, Chairman & Managing Director, Dr. Lal PathLabs Ltd.), inaugurated this latest innovation from the house of Transasia. Laura XL System is a fully automated urine chemistry and sediment analyzer, which has been developed in-house by Transasia’s group entity Erba Lachema, Czech Republic. The launch announcement was also featured in the Mumbai edition of The Indian Express.
The sessions were well coordinated and convened by Dr. Mehul Desai (MD Pathologist, Yash Clinical Laboratory, Surat) for hematology and Dr. Vipul Patel (Chief Pathologist, Sunflower Laboratory,Surat ) for coagulation.
“Since its inception, Transasia’s focus has been on meeting the needs of doctors and patients by providing reliable, affordable and innovative medical diagnostic systems. With the introduction of Laura XL, we have further expanded our product portfolio. Laura XL is a fully automated urine analyzer with 21 classifications using artificial intelligence,” said Mr. Suresh Vazirani, Chairman & Managing Director, Transasia Bio-Medicals Ltd.
Dr. Jyoti Kotwal (Prof. & Head - Dept. of Hematology, Sir Ganga Ram Hospital, New Delhi) threw some light on ‘Increased thrombotic tendency amongst soldiers stationed at Siachen’ while (Retd.) Maj. Gen. G.D. Bakshi proved to be a crowd puller in his tete-a-tete on Army’s Role in J&K where he shared some personal reminiscences and interesting medical aspects.
“A sophisticated artificial intelligence is responsible for the automatic recognition of sediment on the pictures, resulting in fast and accurate classification and quantitative determination of the sediment content,” stated Dr. Suchan Pavel, Global Product Manager, Urine Chemistry & Microbiology, Erba Lachema s.r.o.
During the Plenary sessions, pathologists from across India, were keen to know how Dr. Arvind Lal created India’s most valued and trusted pathology network, as he shared his success story. In the second session, Dr. Swati Pai emphasized on ‘Quality Assurance in Hematology’.
In addition, Transasia put together three workshops in clinical chemistry,
In addition, non - clinical sessions by Transasia received an overwhelming response from the delegates for providing a refreshing change from the technical workshops!
With stalwarts from all across the nation, eminent faculty and diverse topics, the APPI conference was a grand success! Medical Device ASIA | July-August 2016 | 23
CPhI Istanbul hosts government and industry to strengthen Turkey as MENA pharma hub 300 content sessions and stimulating new ideas new ideas to propel Turkey towards a top-ten pharma economy CPhI Istanbul 2016, (#cphiistanbul) organised by UBM EMEA, returns for the third consecutive year to Turkey, co-located with InnoPack, ICSE and P-MEC. The fourin-one event will take place at the Istanbul Congress Center (ICC), Turkey, from the 1st to the 3rd of June 2016, and is heavily supported by the Ministry of Health (Turkish Medicines and Medical Devices Agency) and the Pharmaceutical Manufacturers Association of Turkey (IEIS) – highlighting the integral role it is playing in stimulating regional growth. In total, the event is forecasted to attract over 4,200 attendees and over 200 exhibitors, with attendance from regional heavyweights such as DEVA, Nobel Ilac, and Pharmactive. 24 | July-August 2016 | Medical Device ASIA
T
urkey is already established as the regional pharmaceutical hub, and having experienced the fastest growth rate in the OECD – averaging 6.7% per year from 2011-2018 – it is positioned to emerge as a top ten global healthcare economy by 2023. Key to this transformation is CPhI Istanbul, which will run a high level conference in parallel to the exhibition – specifically designed to provide vital market information, key growth opportunities, and create new strategic alliances to ensure future business success.
The Turkish pharma market has an end-user spend of US $9.1 billion and is already the seventh largest in Europe, with around 80 production facilities, 20,000 employees and direct access to the pharma markets of the Middle East and North Africa. As a result, CPhI Istanbul has seen rapid growth and has cemented its role as the key event for pharmaceutical solution suppliers from across Turkey, the Balkans, the Middle East and North Africa, and South East Europe. Another factor contributing to rising
international interest is that the Turkish pharma market still relies heavily on imports, representing 50% of the total industry output. However, a critical consideration for international suppliers looking at market entry is access to robust business intelligence to inform better decisions about the right opportunities to pursue. CPhI Istanbul is helping disseminate this market knowledge through its free-to-attend conference. This will focus on an evaluation of key legislative and regulatory updates, providing sound advisory intelligence and independent practical insights for pharma manufacturers, suppliers and buyers. The programme is built around six core areas: ‘Policy & Regulation’, ‘Business & Investment’, ‘Manufacturing’, ‘R&D, Innovation & New Technologies’, ‘Supply Chain’ and ‘Foreign Markets’. The conference bridges both East and West perspectives, and key sessions include: ‘Positioning Turkey as a Regional Pharmaceutical Hub’; ‘Creating an R&D Centre Based on Entrepreneurship & Innovation: The Case for Turkey as a Pharmerging Country’; ‘Generating Value through Innovation: What the Turkish Pharma Industry Has to Offer within MENA Context?’; and ‘The Case for Turkey: Transition from Import to Local Production in Pharmaceuticals and Subsequent Need
for Harmonising Supply Chain Structures’. Orhan Caglayan, Group Director at UBM Turkey, commented: “This event has already been a huge success in the last 3-years and continues to showcase both the international and domestic appetite for pharmaceutical business. With many international attendees, and the support of regional industry and government, this event is now integral to the progressive advancement of manufacturing. It’s a diverse and evolving market, so to maximise the opportunities available, CPhI also provides a huge content platform to help both attendees and exhibitors make better-informed decisions and see the full scope of potential in this high-growth region.” Other highlights at CPhI Istanbul 2016 include: • For the first time, CPhI’s eponymous Matchmaking Programme comes to Istanbul –complimentary to all attendees – this programme provides the opportunity to actively target the companies that best match individual business needs. It includes a dedicated area solely designated to hosting meetings and allows attendees to pre-plan their schedules and make the most productive use of business opportunities. • Round Table Sessions will be held, with representatives including analysts, consultants, regulatory bodies, academics and pharmaceutical manufacturing companies. Each 30-minute session
will focus on the full spectrum of business critical and pharma market issues, with a maximum of 10 attendees at a time. • CPhI Istanbul is also a part of the Hosted Buyers Programme from the Turkish Ministry of Economy, which allows for the costs of eligible buyers to be covered by the Turkish Government. • C-Summit, supported by Fortune Turkey Magazine, gathers the leading CEO’s in the Pharma industry to discuss key issues in the market. This high level summit will take place on the show floor, with discussions centered on how to establish long-term partnerships in Eurasia, market advantages and limitations, as well as the road map for next five years in the region. • Finally, the Women’s Networking Breakfast will feature a panel discussion on “Breaking the Glass Ceiling” and is designed to support networking and further empower female executives as business leaders in pharma. “At our booth we had the opportunity to meet most of our business partners and distributors. Our beautiful city Istanbul attracted many international visitors to join CPhI, which provided business development opportunities between companies from different continents.” Ms. Sibel Nitelik Ödemiş - API Sales Executive & South America Region Account Manager, MN Pharmaceuticals To register online and learn more about CPhI Istanbul visit: http://www.cphi.com/istanbul/
Medical Device ASIA | July-August 2016 | 25
Top Medical Technology Companies that are Helping Humans to Live Longer Curing people of disease is the Holy Grail of medical technologies but there are some that achieve an equally difficult task - they extend life in very sick people. General Electric GE is a household name and is a well-known conglomerate known for making large medical devices such as MRI machines. But it has also developed the Vscan portable ultrasound device that is now being used in rural parts of the world where pregnant women don't have easy access to prenatal care. The company's healthcare division is based in Waukesha, Wisconsin
Ossur
B
elow is an infographic of few companies that are helping people to live longer. The infographic compiled by an online site that helps people with undergraduate nursing degrees get a higher education, shows that these life-extending companies are those that make medical devices. They are:
SynCardia Systems This company, with headquarters in Tucson, Arizona, makes a temporary total artificial heart for patients who are waiting, sometimes as long as a year, before a heart transplant procedure can be performed on them. It is the world's first and only FDAapproved total artificial heart. A 10year clinical study that supported the FDA found that 79% percent of patients who were given the temporary heart lived long enough
Second Sight to receive the heart transplant.
Intuitive Surgical This Sunnyvale, California company makes the Da Vinci surgical robots and is for the most part a big success story in the world of medical devices. The laparoscopic robotic surgery devices can be manipulated remotely by a physician and because a robot is performing the procedure, patients suffer less pain, less blood loss and lowers the need for blood transfusions. People can also resume their normal routines sooner. The devices can be used in a variety of surgical procedures including urology, cardiothoracic and gynecology among others.
26 | July-August 2016 | Medical Device ASIA
Based in Sylmar, California, Second Sight makes prosthetic implantable eye devices for the blind. The Argus II Prosthesis Retinal System helps patients whose outer retina has degenerated to see better. The device has a humanitarian
This Reykjavik, Iceland, company manufactures various prostheses including the intelligent Power Knee, the world's only motor powered knee for above knee amputees. The device is designed such that it takes less energy for amputees to move by restoring the power of the loss knees.
Envoy Medical
It also allows them to climb stairs, a simple task rendered near impossible for people who have lost their knees.
This company with headquarters in
Harvard Bioscience
device exemption from the FDA.
St. Paul, Minnesota, is all about improving hearing. It makes the Esteem implantable device hat helps to restore hearing. The company's device was approved by the FDA in 2010 and is aimed at people who experience moderate to severe sensorineural hearing loss.
The company, based in Holliston, Massachusetts makes a variety of life science tools, which includes bioreactors. The company made the stem cell solution that covered an artificial trachea and helped that organ be seeded with the cells needed to create a functioning windpipe.
MEDICAL FAIR ASIA introduces inaugural sports medicine conference for its 2016 iteration The inaugural MEDICAL FAIR ASIA MEDICINE + SPORTS CONFERENCE will be held on the 1st September 2016. The conference will be colocated with MEDICAL FAIR ASIA, the region’s premier medical trade fair at The Sands Expo & Convention Centre at Marina Bay Sands in Singapore. The organisers of the MEDICINE + SPORTS CONFERENCE, Messe Düsseldorf Asia (MDA), were inspired by the success over the past three iterations of the MEDICA MEDICINE + SPORTS MEDICINE CONFERENCE which was staged at the world-famous MEDICA in Düsseldorf, Germany. MEDICA, the world’s largest medical trade fair is also organised by Messe Düsseldorf. The MEDICAL FAIR ASIA MEDICINE + SPORTS CONFERENCE aims to forge links within the international sports medicine ecosystem and the interdisciplinary exchange between international sports medicine experts, professional athletes and the sporting goods and healthcare industry. The Asia-Pacific sports medicine market is growing at a compound annual growth rate (CAGR) of nearly 7 percent and is expected to be worth US$3.95 billion (S$5.3 billion) by 2019. As well as catering to the sporting community and industries, MEDICAL FAIR ASIA MEDICINE + SPORTS CONFERENCE also aims to contribute to preparing not only exercise experts but also primary healthcare providers and physicians for helping ageing populations prevent lifestyle and geriatric diseases such as heart disease, diabetes, obesity and osteoporosis. Asia’s growing middle classes and ageing populations are creating a huge market for such services; in Singapore alone, the healthcare expenditure is projected to reach S$12 billion by 2020 according to Finance Minister Tharman Shanmugaratnam at the budget debate in Parliament in March 2014. The MEDICAL FAIR ASIA MEDICINE + SPORTS CONFERENCE provides a networking platform for interdisciplinary dialogue and development of solutions. Attendees of the conference will be able to put their fingers on the pulse of the industry by tuning in to keynote speakers who will share their expertise on main topics such as physical activity as a key to disease prevention, defining health and fitness guidelines, creating the right activity programmes for athletes and non-athletes, vital data and performance monitoring, and digital systems in elite and recreational sports as well as innovative sports medical solutions. The programme consists of four exciting and insightful sessions on important, innovative topics: Session 1 - How to Create and Implement Health Guidelines The aim of this session is to underline the importance of Exercise Medicine, the role of physical activity in healthcare as well as the development of suitable health and fitness guidelines. This will be done via keynote presentations and a panel discussion with industry experts. Session 2 - Personalizing Training Programmes & Equipment Session 2 is all about the personalisation of training. Presentations will delve into individual programmes for training and regeneration,
personalising medical products and equipment and hybrid personal coaching and training. Session 3 - Latest Innovations in Monitoring Vital Data and Sport Performance Vital data and performance monitoring, new approaches and trends in monitoring as well as best practices in monitoring corporate health will be among the topics to be explored. Session 4 - Digital Innovations in Recreational and Elite Sports The conference presentations will conclude with an examination of the field of new technologies with speakers tackling digital systems in elite and recreational sports, wearable technologies, monitoring of different vital data parameters, and the measuring and training of cognitive and emotional parameters.
Confirmed speakers include: 1. Dr. Ben Tan, Chief, Department of Sports Medicine Changi General Hospital and Chairman of Exercise is Medicine (EIM), Singapore. 2. Dr. Joni Kettunen, CEO, Firstbeat. 3. Dr. Visit Thaveeprungsriporn, Executive Director, Zensorium. 4. Malia Ho, Principal Podiatrist, Singapore Sports Medical Centre. 5. Ping Kow, Director, Well Being Digital Limited. 6. Steve Leftly, Director, MYOVOLT. 7. Alexis Zervoglos, Chief Business Officer, Qardio. The conference will take place on the trade show floor and attendees as well as interested exhibitors can find the MEDICAL FAIR ASIA Sports Medicine Pavilion located in the vicinity. To register for the conference and for further information, visit www.medicalfairasia.com
About MEDICAL FAIR ASIA 2016 MEDICAL FAIR ASIA 2016 is an international medical trade fair targeted at decision makers in the medical industry ranging from healthy ministry officials, hospital managers and employees, administrators and operators of rehabilitation organisations, nursing homes and organisations for the disabled to healthcare professionals (HCPs) including doctors (surgeries and hospital), nursing officers, hospital technicians, biologists, pharmacists, and visitors from industry and commerce. The 2014 iteration attracted 10,780 visitors, of which 40 percent came from outside Singapore. For more information, please visit www.medicalfair-asia.com
About Messe Düsseldorf Asia Messe Düsseldorf Asia is a subsidiary of Messe Düsseldorf in Germany, one of the world’s leading trade fair organisers, responsible for organising more than 20 global No. 1 exhibitions in various industries including medicine and health, specifically MEDICA, COMPAMED and REHACARE INTERNATIONAL held in Düsseldorf, Germany. With extensive expertise in organising trade fairs in Southeast Asia, Messe Düsseldorf Asia has developed a portfolio of numerous trade fairs in the region since 1995. For more information, please visit http://mda.messe-dusseldorf.com/
Medical Device ASIA | July-August 2016 | 27
10th COMPAMED Spring Convention: expert forum focuses on the megatrend of personalised and individualised medicine “New insights into the molecular processes of life enhance our understanding of health and disease. Individualised medicine seeks to put those insights to use for all: for tailored prevention, diagnosis and treatment,” goes the Federal Ministry of Health and Research’s description of individualised medicine, an approach commonly also known as personalised or personal medicine. Innovative micro- and nanotechnology solutions are helping to enable the development of diagnostic and treatment processes tailored to address the individual patient’s disease progress, personal needs and distinctive features. Personalised medicine points the way forward and was the dominant theme of this year’s COMPAMED Spring Convention, which was co-hosted by Messe Düsseldorf and IVAM Microtechnology Network on 24 May in Frankfurt am Main. The event, which celebrated its tenth anniversary this year, provides a platform for experts to discuss ideas in the run-up to COMPAMED, the leading international trade fair for medical technology industry suppliers. 28 | July-August 2016 | Medical Device ASIA
“
The Spring Convention always gives a preview of the trends at the forefront of technical and business discussion at November’s COMPAMED trade fair and accompanying forums. The emphasis is on general trends in medical technology and their relevance for medical technology suppliers, who are key cooperation partners in product development,” said Horst Giesen, Global Portfolio Director Healthcare, Messe Düsseldorf, explaining the conceptually coordinated interactive approach.
Medical technology evolution offers opportunities for suppliers Medical devices are becoming ever smaller, lower-cost and better connected. Accordingly, medical technology companies require suppliers to deliver ever finer, more lightweight yet more powerful components, modules and chips, or dedicated energy and data storage systems. “Medical technology comes to the person, not the person to the technology” could be the credo of the move towards personalised medicine. “At the same time, more and more people are developing chronic diseases,” noted COMPAMED Spring Convention speaker Dr Florian Frensch, Philips Head of Strategy & New Business Development for the Germany-Austria-
Switzerland (“DACH”) region. There are more than 18 million obese people in Germany alone, 20 to 30 million people with high blood pressure, and an estimated eight million will have diabetes by 2030. In return, so to speak, personalisation and digitisation are changing our lives and transforming healthcare delivery: as many as 54 percent of people in Germany think individual treatment methods are very important, and one in 5 of the country’s population has a healthcare or medical app on their smartphone. The health apps market is projected to grow ten-fold in the period from 2013 to 2017. For medical technology manufacturers like Philips, megatrends such as commoditisation, miniaturisation and connected devices are of special interest. Ultrasound is an example of commoditisation: whereas a machine cost about USD 15 000 in 1995 and was larger than an office cabinet, the latest model, “Lumify”, is priced at USD 200 (approx. EUR 177) per month. For that price, customers get a mobile, app-based ultrasound solution which offers safe cloud technology and high image
quality to a large community of healthcare providers. The ultrasound transducer is connected up to an ordinary commercial tablet PC or smartphone. Miniaturisation is similarly evident: a handy point-ofcare device that is easily brought to the patient replaces an entire hospital lab. Digitisation connects it all: “HealthSuite,” a powerful cloud-based platform provided by Philips, enables connected, continuous healthcare. The technology collects, compiles and analyses medical and other health data from a wide range of sources. The solution addresses the complexity of cutting-edge healthcare IT and has the capability to combine conventional health data from digital patient files, diagnostic and imaging systems, and clinical monitoring
with personal data from smartphones, smartwatches and fitness trackers. Piecemeal collection of diagnostic and treatment data in a largely episodic health care system thus gives way to a continuous health monitoring approach offering proactive and preventive benefits.
Rapid analysis of infectious diseases in just 30 minutes The Austrian Institute of Technology (AIT) in Vienna develops technologies for point-of-care lab diagnostic systems, including highly sensitive biosensors for molecular diagnostic tests on body fluids such as serum, urine and saliva. Diagoras, a project that has received EUR5.5 million EU funding, sees the Viennese organisation working with
Medical Device ASIA | July-August 2016 | 29
eight European partners to develop a mobile device that enables doctors and dentists to diagnose and evaluate infectious diseases in just 30 minutes. Patient samples are entered in a system resembling a CD. The reagents needed for detection are already included. The results are displayed by optical methods (fluorescence and luminescence). The reader is the size of a cassette recorder. “Our main task is to develop nucleic acid-based assays. The DNA and RNA strands are specific to a variety of bacteria and viruses,” Dr Giorgio C. Mutinati, AIT project manager said at the COMPAMED Spring Convention. Diagoras has two main goals: to develop a point-of-care diagnostic device based on a microbiology platform intended mainly for use in the diagnosis of oral and respiratory infections.
Efficient methods for complex diagnostic questions Despite advances in treatment, cancer is still a leading cause of death in Germany. Detection of tumour cells that have dispersed in the body is attracting interest both as a diagnostic tool and as a predictor of prognosis. Research indicates that disseminating cancer cells could play an important role in cancer screening. “Blood will continue to be the main source of in-vitro diagnosis,” says Dr Lukas Richter, Siemens Healthcare. The main hindrance to implementing the latest insights in clinical practice is the complexity and cost of currently available detection systems. No high-quality, easy-touse system suitable for routine practice currently exists 30 | July-August 2016 | Medical Device ASIA
that is capable of continuous, real-time detection of isolated tumour cells. The “MRCyte” project funded by the BMBF (German Ministry of Education and Research) and taking place with the participation of Siemens was launched to address this issue. The aim is to measure concentrations of rare cells in patient blood by magnetic detection with a hard drive read. This platform technology based on magnetically labelled cells and matching sensors is called magnetic flow cytometry (“MRCyte”). The new method is much faster and easier to use than the existing technology of optical flow cytometry, especially in the pre-diagnosis stage. “The functions of a living cell would be the ideal biomarker for many clinical decisions. We want to measure non-stable biomarkers in future and reduce pre-diagnosis to a minimum,” Richter said. “MRCyte” may help achieve that. Ever smaller and better point-ofcare devices that deliver rapid
image data and efficient diagnosis of infectious diseases and cancer: all these things are aspects of personalised medical technology. They call for innovative micro- and nanotechnology solutions on the part of medical technology industry suppliers, such as will be presented and highlighted at COMPAMED 2016 in Düsseldorf (14 – 17 November). Tiny sapphire implant shells Implants play an important role in medicine, including individualised medicine. The Centre Suisse d’Electronique et de Microtechnique SA (CSEM) has developed new non-metal miniaturised shells for implants. These special “packaging systems” open up new opportunities for implantation technology because they can be used in hitherto inaccessible parts of the body. “The challenge begins with the inhospitable surroundings implants are exposed to, including an environment that is highly corrosive because of the oxidation
processes, pH, temperature, ion composition and protein concentrations in our bodies,” Rony Jose James, CSEM, said at the COMPAMED Spring Convention. What’s more, implants also have to be biocompatible and biofunctional, which includes being non-toxic and having a long service life. Various materials used in microelectronics were considered, but the chosen solution consists of a tiny sapphire shell that measures just 0.6 by 0.6 by 1.0 millimetres but offers enough space for miniature sensors. “The spectrum of applications is wide-ranging, including implantable microphones in the middle ear, aneurysm detection, neurostimulation implants, and monitoring vital life functions in the heart,” James said. For Micromotion, too, small is all. The company specialises in new solutions based on micropropulsion technology, which is increasingly required in medicine and elsewhere. “Personalisation calls for smarter devices. This means increased automation of the devices coupled with increasingly complex functionalities, which in turn requires more complex control, sensor and actuator technology,” Dr Reinhard Degen, general manager of Micromotion, reported at the Spring Convention. This prompted the company to develop robust, exceptionally durable and reliable electromechanical actuators, which present valuable performance benefits in addition to small size. These include biocompatible materials, high precision, zero backlash, high gear ratio,
small number of components and low maintenance. Biological tissue from 3D printers 3D printers are already being used for mass production in many industrial processes, notable examples being lightweight engineering and aviation. 3D printing also holds great promise in medicine. From dental restoration to knee implants to entire organs, the possibilities seem endless. Although a 3D printed heart, liver or kidney may be beyond reach for some time to come, 3D printing in medicine has long begun. “It opens up the possibility of converting digital data directly into objects. Fabrication into individualised forms is very much to be desired in medicine, and plenty of 3D data is already available as a result of high-tech imaging methods,” said Dr Kirsten Borchers, Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB), outlining the excellent starting position. IGB has gone on to develop bioinks for bioprinting,
which are produced from gelatine and used to construct chemically crosslinked hydrogels. Gelatine is derived from collagen and closely resembles the natural extracellular matrix. By varying the degree of crosslinking, IGB researchers can produce a matrix of a strength that is compatible with natural tissues such as fat or cartilage. “We modify biomolecules from the extracellular matrix of tissue in a way that enables us to control its gelling behaviour, viscosity and crosslinkability, thus rendering it suitable for use in the bioprinting process,” Borchers said, describing the complexity involved. The 10th COMPAMED Spring Convention again delivered a glimpse of the trends and developments shaping medical technology and medical technology industry suppliers – the ideal warm-up for COMPAMED 2016 (14 – 17 November). The leading platform for medical technology suppliers is once more expected to
Medical Device ASIA | July-August 2016 | 31
attract 800 exhibitors from more than 40 nations, filling Düsseldorf Fairground halls 8a and 8b to capacity. More than 18 800 visitors thronged to last year’s COMPAMED, the highest attendance ever. 130,000 trade visitors from about 120 nations attended MEDICA and COMPAMED 2015 altogether. In a globally unique dual combination, the world’s largest medical trade fair, MEDICA (approximately 5000 exhibitors) and COMPAMED reflect the entire process chain and present a full range of the medical devices, systems and instruments now available. Both shows together take up the whole Düsseldorf Fairgrounds complex (19 halls).
32 | July-August 2016 | Medical Device ASIA
Government of India, Registrar of Newspapers of India (RNI)#: DELENG/2009/30008
MEDICA 2016 + COMPAMED 2016:
Trend barometer of a dynamic market Booking demand confirms a high level of satisfaction with the event’s new schedule When top decision-makers in the healthcare business meet in Düsseldorf again in the middle of November at the world’s leading medical trade fair, MEDICA 2016, (scheduled date: 14 – 17 November 2016; Monday to Thursday), 5,000 exhibitors from around 70 countries will be presenting themselves once more as partners in unchanged enthusiastic innovation – offering tailored solutions for outpatient and clinical care. According to the European Patent Office, in 2015 no other technological sector submitted as many patent applications worldwide as the field of medical technology. 34 | July-August 2016 | Medical Device ASIA
“The course of registrations up until now is showing that the incredibly high level of participation seen in the previous year can be expected again, thereby indicating a high level of satisfaction among exhibitors with the new schedule of the event, running from Monday to Thursday,” explains Joachim Schäfer, managing director of Messe Düsseldorf. He is also pleased about the development of the trade fair for medical technology suppliers being held in parallel, COMPAMED. “Here as well, the change of schedule has been positively accepted by the exhibitors, and the extension of COMPAMED by an additional day has been expressly welcomed. This can also be seen by a high rate of repeat bookings. Once again, we expect a turnout of more than 800 exhibitors in the fully booked COMPAMED halls, 8a and 8b.” Concerning innovations, the market at the moment is characterised by a special dynamic of important supplier trends.
The digitalisation of healthcare is progressing at an unstoppable rate, and this concerns all fields, outpatient and clinical care, as well as patients and physicians alike. With reference to Germany, the latest enacted E-health Act should ensure that the networking of stakeholders within the scope of the healthcare process is considerably optimised by means of a more effective collection and utilization of patient data – at least this has been stated as its clear goal. The predominant “digital patchwork” up until now pertaining to intrinsically sophisticated, but poorly compatible solutions could now be woven into a better overall system using a better integration of data.
Innovations in focus and great prominence “waiting in the wings” MEDICA 2016 visitors will be able to see for themselves what the digital future in the healthcare sector will be like via the exhibitors’ many innovations as well as the lectures and presentations at the MEDICA CONNECTED HEALTHCARE FORUM (with the MEDICA App COMPETITION) or the MEDICA HEALTH IT FORUM (each in hall 15).
In particular, “wearables” and smartphones in combination with special health apps, which can also be used by patients themselves, have the potential of becoming an indispensable element of networked health in the future. Numerous new products relating to this topic have been already presented at the MEDICA 2015, and countless other mobile health applications are currently under development, whereby many focus on cardiovascular diseases, diabetes as well as the remote monitoring of therapies. Here a particularly high level of user potential can be expected in the future with regard to patient numbers. The topic of big data also continues to be a focus of visitors’ inter-
est. At its core, it has to do with compiling and evaluating enormous amounts of patient data in order to be able to gain knowledge with regard to the development of and effective therapy for certain diseases. The MEDICA ECON FORUM will also be dealing with the opportunities and consequences of healthcare digitalisation. The forum (in hall 15), organised as a joint effort between the Techniker Krankenkasse (a German statutory health insurance company) and Messe Düsseldorf, has been firmly established as a platform for health policy dialogue, shown by the confirmations of prominent guests to again attend this year’s event. Those who have already confirmed their participa-
Medical Device ASIA | July-August 2016 | 35
surgery.
cine, toxicology and hygiene”.
Conferences directly integrated into the specialist trade fair
With reference to the MEDICA conference programme, furthermore, the 39th German Hospital Conference as a leading event for the directors and management of German hospitals, the international DiMiMED conference for specialists from the field of disaster and military medicine as well as the MEDICA PHYSIO CONFERENCE will be forming a close content-oriented link to the topics of the specialist trade fair – aimed toward the specific interests of their respective participant target groups.
Such important medical technology trends will not only be represented by exhibitor innovations at the MEDICA, but will also be reflected within the scope of the programmes of the accompanying conferences. For example, these include the MEDICA MEDICINE & SPORTS CONFERENCE, dealing with the use of applications in close proximity to the body and “wearables” for monitoring vital signs, or the MEDICA EDUCATION CONFERENCE.
tion include, among others: The Federal Minister of Health, Hermann Gröhe, the NRW Minister of Health, Barbara Steffens, or also Maria Klein-Schmeink, health policy spokeswoman of the Bundestag parliamentary group Alliance 90/The Green Party (Bündnis 90/Die Grünen).
The third dimension is finding its way into operating theatres Not only bits and bytes are affecting the healthcare business, however. Medical technology also has exciting topics to offer. At the moment, innovations for interventional procedures are seen as particularly important. In the case of modern surgery procedures, an “integrated” approach is in demand. Data deriving from medical imaging flows into the controls of surgical assistance systems. They can even be generated during surgery by imaging systems directly available in the operating theatre, ensuring that the intervention can take place in a precise and gentle manner. Here, above all, progress in the field of endoscopy and instruments for minimally invasive surgery translate into great benefit. Currently, the third dimension is increasingly finding its way into operating theatres. In the case of so-called 3D laparoscopy systems, there are two image sensors that are precisely aligned with each other at the end of the endoscope, providing the surgeon with a lifelike endoscopic 3D image during the course of minimally invasive 36 | July-August 2016 | Medical Device ASIA
This conference is being organised this year for the third time by the German Society for Internal Medicine (DGIM) and offers participants an excellent opportunity to gather and exchange information on new technologies and their medical use as part of a scientific training event held in parallel to the world’s largest medical trade fair. Of the four conference days, each individual day offers a particular thematic focus. Along with innovations in the field of 3D laparoscopy, among other things, the event will be started off with “New operative techniques during surgery”. On the other days, the MEDICA EDUCATION CONFERENCE will be dedicated to imaging and interventional procedures (e.g. magnetic resonance tomography and sonography), future technologies for internal medicine (e.g. remote monitoring in the case of chronic disease) as well as, on the event’s last day, “Diagnostics in the fields of internal medicine, laboratory medi-
Now, and in the future, a central strength of the MEDICA continues to be that it does not just deal with solutions for one individual medical specialist discipline at a time, but that it offers solutions for the complete “workflow” of patient treatment. The individual focuses of the MEDICA trade fair, which are clearly structured according to hall, include: Electromedicine/medical technology (more than 2,500 exhibitors), laboratory technology/ diagnostics, physiotherapy/orthopaedic technology, commodities and consumables, information and communication technology, medical furniture and specialist furnishings for hospitals and doctors’ offices.
COMPAMED – hotspot for complex hightech solutions This year, once more in parallel to the MEDICA, the COMPAMED with approx. 800 exhibitors will be taking place for the 25th time. Always scoring top annual results with reference to the number of exhibi-
tors and visitors, it has long since developed into the leading international marketing communication platform for suppliers of the medical technology industry. Where, at one time, simple parts, components and equipment for technical devices and medical products had primarily been presented, today, COMPAMED is a hotspot for complex high-tech solutions. Here, the microsystem technology solutions for mobile diagnosis, monitoring and therapy systems are particularly in line with the current trend. These include, among others, smart sensors and energy storage systems for use in “wearables”, microtechnology applications for intelligent implants or printed electronics. In addition, the subcontracting and outsourcing of services for all elements of the process chain (R&D, production, supply chain management, quality management, spare parts handling, etc.) are continuing to gain in importance. With 18,800 visitors last year, the COMPAMED broke its best record so far. A total of 130,000 specialist visitors from around 120 countries toured the MEDICA and COMPAMED in 2015. This unique combination allows MEDICA and COMPAMED to represent the entire process chain and the full range of medical products, devices and instruments. Together, they keep the Düsseldorf trade fair complex (19 halls) fully booked. As in previous years, it will be possible to visit both events with a single ticket. Opening hours: 10:00 am - 6:30 pm / 14 – 17 Nov. 2016 Medical Device ASIA | July-August 2016 | 37
98.4°® collaborates with MobiKwik to become the first pharmacy chain to adopt cashless paymentsa
9
8.4°®, a leading chain of retail pharmacy stores by Global Healthline, today announced its collaborations with MobiKwik, India’s largest digital payments company to allow its user to facilitate cashless payments across its stores. This is the first time that a mobile wallet is being integrated across a chain of retail pharmacies. “In the rapidly evolving digital age, mobile wallets are empowering consumers with convenient, speedy, safe and reliable cashless payment solution. 98.4°® and Mobikwik collaboration supports our commitment towards enhanced customer experience.” said Mr. Sachin Mirza, Head – Marketing & Business Development, Global Healthline. “We look forward to welcome and extend our personalised pharmacy care services to over 30 million Mobikwik users in India.” Mr. Mirza added. Speaking on the announcement, Mrinal Sinha, COO, MobiKwik said, “as a first step to taking the MobiKwik offering to the medical industry, we have partnered with 98.4°®. We hope that the end users will benefit hugely with quick processing of payments across98.4°® pharmacy stores.”
About 98.4°® 98.4°®, is a leading chain of retail pharmacy stores providing trusted pharmacy care services for over 14 years with operations in 27 elite neighbourhood of Delhi & NCR. With over 2 million interactions a year, 98.40â has gone beyond normal retailing by offering them a one-stop solution for genuine medicines, aesthetically beautiful stores and educated pharmacists to address their needs. As a full service pharmacy, 98.40â offers its customers a large range of prescription medicines, critical care, OTC products, Hair and skin care, Baby care, Personal care, Health Foods, Health Supplements, High-end perfume. Furthermore, 98.40â ensure that products are kept at the right temperature and are displayed right, keeping in mind that the customer can touch, feel and choose. In addition to the pharmacy care services, 98.4°® also provides its customers convenient access to advanced diagnostic services through it’s collaboration with world’s leading laboratory of USA that offers over 3400 specialised tests. Today, over 300,000 98.4°® customers are members of its Total Health Loyalty Program who benefit from extraordinary rewards and savings on their shopping at the 98.4°® stores. About MobiKwik MobiKwik, is India’s largest independent mobile payments network, connecting
32 million users with 100,000 retailers. Founded in 2009 by Bipin Preet Singh and
Upasana Taku, the company has raised three rounds of funding from Sequoia Capital, American Express,Tree Line Asia, MediaTek, GMO Payment Gateway and Cisco Investments. MobiKwik aspires to be the largest source of digital transactions in India. One of the leading digital payments platforms for online and offline merchants,
MobiKwik is powering payments for IRCTC, Uber, Meru Cabs, Big Bazaar, OYO Rooms, Zomato, PVR, Archies, WHSmith India, BookMyShow, Grofers, Big Basket, Domino’s, Burger King, Pizza Hut, eBay, ShopClues, Myntra, Jabong, Pepperfry, Barista, Food Panda, nearbuy, Van Heusen, Allen Solly, Louis Phillips, GoDaddy, MakeMyTrip, Cleartrip, and Yatra. 38 | July-August 2016 | Medical Device ASIA
INTELSIUS EXTENDS ITS ORCA RANGE FOR THE TRANSPORT OF WHOLE BLOOD PRODUCTS
Technical Services Manager Neil Sherman commented: “The addition of this PCM means that ORCA is now even more adaptable to meet our client’s exact requirements. The introduction of +22°C Plantol demonstrates Intelsius’ commitment to innovation
I
ntelsius, a DGP company, a designer, manufacturer and distributor of temperature-controlled packaging solutions, based in York, has extended its ORCA range, with the introduction of its +22°C Plantol PCM.
The +22°C Plantol PCM is the company’s latest addition to its proprietary range of Phase Change Materials and is manufactured specifically to the temperature range 2024°C for the transportation of whole blood products. With the now greater need for more complex shipping systems the +22°C Plantol provides an extended solution to the ORCA range, providing exemplary performance as an ambient PCM in hot conditions over 144 hours against ISTA 7D, for every sized ORCA.
and meeting the greater complexity of today’s global shipping requirements.” Intelsius’ PlantolTM range of PCMs are non-toxic and non-fossil fuel derived and have been designed for exceptional performance with minimal environmental impact.
About Intelsius Incorporated in 1998, Intelsius is a subsidiary of DGP Life Science Ltd. Intelsius serves a wide range of organisations including government agencies, leading pharmaceutical companies, clinical researchers, major laboratories and life sciences organisations. Intelsius is the preferred response partner for human and veterinary epidemic and pandemic events in the UK and the Republic of Ireland. Intelsius provides intelligent, thoroughly tested and qualified packaging systems that meet regulatory compliance standards worldwide. The company also offers solutions to ensure the integrity of customers’ products and samples for better human and animal health worldwide. Intelsius has a growing global presence with headquarters in York, United Kingdom and manufacturing facilities, distribution hubs and local offices situated in North America, Europe and Asia. For more information visit www.intelsius.com.
Medical Device ASIA | July-August 2016 | 39
Leading experts reveal how exon-focused microarrays are advancing genetic syndrome research OGT workshop at ESHG highlighted the impact of exon-level CNV analysis on accurate detection of genetic disorders
T
Oxford Gene Technology (OGT), The Molecular Genetics Company, held an exclusive workshop exploring the power of exon-focused microarrays in enhancing genetic syndrome research at the recent European Human Genetics Conference (ESHG). Three expert clinical researchers from across the globe shared their knowledge of enhanced CNV detection with OGT’s CytoSure™ Constitutional v3 array, helping viewers understand how to implement the next generation of microarray into their laboratories. A validation programme from one of the speakers is also available as an application note. 40 | July-August 2016 | Medical Device ASIA
he most up-to-date array platform for CNV detection currently available, OGT’s CytoSure Constitutional v3 array, targets all relevant genes and regions from ClinGen*, the Clinical Genome Resource, and the Deciphering Developmental Disorders (DDD) project. With up to 502 of the most disease-relevant genes targeted with high probe density, the array provides single-exon-level resolution. Enabling the detection of single-exon aberrations has proved valuable in many laboratories, including the West Midlands Regional Genetic Laboratory (Birmingham, UK). In his talk at ESHG, consultant clinical scientist Dominic McMullan, described the implementation of the CytoSure Constitutional v3 array in the NHS laboratory, and how it facilitated cost-effective, evidencebased analysis of large populations. He commented: “Our decision to switch to OGT over alternative platforms was based largely on the quality of the evidence base behind the array design, allowing for a very comprehensive analysis of exons, genes and regions key in postnatal and prenatal applications. Following a rigorous validation, we found this platform out-performed all others.” Guiding viewers through the validation process in more detail, Dr Kris Van Den Bogaert from UZ Leuven (Belgium) discussed evaluation of the CytoSure Constitutional v3 arrays in prenatal and postnatal research. Prospective validation compared key quality metrics between two platforms, while retrospective
validation analysed concordance with MLPA-confirmed aberrations. From this thorough validation, the new platform was found to increase coverage for clinicallyrelevant regions. The data is available to view in a free application note: “Adoption of the CytoSure Constitutional v3 microarray for increased detection of diseaserelevant variants”. In light of emerging genomic technologies, the latest CNV detection capabilities of the array remains a key part of the clinical genetics research framework, as explained by Professor Madhuri Hegde from Emory University School of Medicine (Georgia, USA). In this talk, she expanded on her work with OGT combining NGS, microarrays — including OGT’s CytoSure DiseaseFocused Research arrays — and an all-inclusive genomic data interpretation platform for comprehensive analysis of genetic disorders. Product Manager at OGT, Anthony Allen, commented: “We’ve been witnessing an increasing trend towards the microarray and NGS being viewed as complementary rather than competing techniques. Professor Hegde’s talk reinforced this concept, and each of our guest speakers provided valuable insights into the ways researchers can implement exon-level CNV detection for more accurate genetic disorder identification.” To find out more about the CytoSure Constitutional v3 array, please visit www.ogt.com/constitutional.
Godrej Appliances to Contribute Towards 30% Reduction in Global Vaccine Wastage Launches latest range of innovative Medical Refrigerators • Godrej Appliances shapes the future of vaccine storage with breakthrough Sure Chill technology; expands the medical refrigerator portfolio with 6 introductions • Aims to reduce vaccine wastage in 90 developing nations • 151 million vaccines-around $750 million, are lost annually due to improper refrigeration in developing countries • Targets 200 crore revenue from medical refrigerator portfolio by 2020 • Plans to set up capacity for 30,000 units over the next 2 years developing and underdeveloped countries. With holdover time of 13 days and just 2.5 hours of power requirement per day, the range was designed to handle extremities.
Over two million children under the age of five die every year in India and another one million or more are disabled for life due to a lack of vaccination or the administration of ineffective vaccines. One of the major factors that render vaccines ineffective is the lack of a robust cold chain infrastructure. Many developing countries have inadequate cold chains – which means that optimal temperature-control mechanisms for the transport, storage and handling of vaccines are not in place. According to a research estimate, approximately 151 million vaccines, equivalent to approximately $750 million, are lost annually due to improper refrigeration in developing countries. (Source: Visible Thinking – Duke Undergraduate research society. http://undergraduateresearch.duke.edu) All vaccines lose potency on exposure to heat above 8°C, while some vaccines are affected when exposed to freezing temperatures. This damage is irreversible and can adversely impact anyone using such affected vaccines. It is therefore crucial that vaccines are stored at the ideal temperature range of 2-8 °C to avoid any wastage. Godrej Appliances, one of the
leading players in the home appliances industry, in partnership with UK-based Sure Chill Company, launched medical refrigerators with Sure Chill technology last year. These specialised refrigerators were designed especially to address the key need of providing precise cooling solutions for vaccines and blood, despite long power outages - common in upcountry remote areas in
42 | July-August 2016 | Medical Device ASIA
Taking this endeavour further, Godrej Appliances has expanded and strengthened its medical portfolio further by launching a range of 6 new models. Keeping in mind the needs of urban and peri- urban areas where power outages are infrequent, the new Lite series is designed with a holdover period of 3 days which gives sufficient time to service and fix the product in case of any downtime. The Lite series has been designed to offer 50% reduction in costs. In light of the limited budgets common to developing economies, this optimized series is expected to boost adoption of the superior Sure Chill Technology offered by Godrej Medical Refrigerators. With the intent to further facilitate the government in its efforts towards 90% immunisation coverage - the mission adopted by Government for its Indradhanush program, Godrej Appliances has also developed an innovative standalone vaccine storage device in the form of a combined fridge freezer for remote health centres. Currently, for every ILR , the health center has to install a deep freezer , which calls for multiple machines to be serviced and maintained, and downtime on any one affects
the outreach programs significantly. Godrej’s combo fridge freezer solution can also run on solar power - completely independently, and one such equipment can cater to 6 outreach programs in a week. This will give the government immense flexibility to set up more remote health facilities and boost actual immunisation coverage while its precision temperature control between 2-8°C will ensure maximum utilisation of vaccines. Godrej Appliances has also identified blood storage as a space that needs technological innovation, as blood storage also requires maintenance of optimum temperature range of 2-6°C. Below 2°C, the blood haemolyses and transfusing heamolysed blood can cause renal failure and fatal bleeding problems and above 6°C blood is at the risk of bacterial contamination. Using the Sure chill technology, Godrej has developed innovative solutions for blood storage and will be focusing on making it available to hospitals and blood banks. Since downtime of these machines affects the immunisation outreach programs and undermines immunisation coverage. Hence, the Godrej Smartcare service promise assumes critical importance here and we are committed to 48 hours of call closure in urban centers and 72 hours in rural centers. Backed by the assurance of 95% spares availability, wide service network
and supported by longest hold over time in the product, this translates into reassuring ‘always on’ performance and no fear of vaccine wastage. With this strong portfolio, Godrej aims to contribute to vaccine
wastage efforts by 30 per cent in developing nations. Speaking on the occasion Mr. Jamshyd Godrej, Managing Director and Chairman, Godrej & Boyce Manufacturing Company Ltd. said, “Immunisation is among the most
powerful and cost -effective of all health interventions. Lack of immunisation not only affects families but also the nation’s productivity and is a burden on the nation’s healthcare and social welfare system. Despite all the progress made on this front, effective immunization continues to be a major challenge globally. We believe that when it comes to immunization, the cost of wastage must not be measured in dollars but in the count of lives lost. Among the most critical of the barriers to effective immunization programs is lack of inadequate cold chain infrastructure. At Godrej, we understand that innovative mechanisms will need to be put in place to help developing countries increase immunization coverage and minimize wastage in order to further build upon the progress made so far. Godrej has always been at the forefront, consistently endeavoring to encourage initiatives promoting healthier communities. Through consistent efforts towards strengthening the medical cold chain infrastructure, Godrej aims to contribute towards 30% reduction in global vaccine wastage through its new range of medical refrigerators developed in collaboration with The SureChill Company UK. “ Mr. Peter Saunders, Chairman, The Sure Chill Company-UK, said, “We are delighted to partner with Godrej Appliances to extend the reach of the Sure Chill technology around the world. We have the potential to save millions of lives. There can be no greater motivation. Traditional cooling technologies don’t protect vaccines effectively. They either fail to sustain cooling when power is lost or expose vaccines to freezing temperatures due to over cooling, resulting in damaged ineffective vaccines and compromised immunization programmes around the world. The Sure Chill technology, which is already used in over 30 coun-
tries, creates a natural and internal energy store that is capable of providing a perfect, constantly chilled storage environment in areas where there is an intermittent power supply. And if there is no power at all, as if often the case in upcountry areas, the system can be teamed with solar power with exactly the same results. With upto 13 days of cooling in ambient temperatures of 43˚C with no power at all, the technology is miles ahead of existing conventional ILRs. “ Mr. Anil Verma, Executive Director and President, Godrej and Boyce Manufacturing Company Limited, said “Godrej has always been an organization with a social conscience. It started with the vision of making India self sufficient and has come a long way in this journey. Healthcare infrastructure is among key pillars of the nation’s growth and we strongly believe that public-private partnerships coupled with the right offering can help address many of the challenges that our current healthcare system faces. Our association with The Sure Chill Company UK is a strategic initiative for Godrej given the company’s focus on health care as a vertical to focus on through its diverse businesses. And like all Godrej offerings, these products are not just high on the innovation quotient but also Good and Green which will build healthier communities across the world, thus bringing alive the Godrej promise of ‘brighter living’. Mr. Kamal Nandi, Business Head and EVP, Godrej Appliances, added, “We have always believed that innovation can help address the toughest of challenges - cold chain infrastructure is not an exception. In partnership with The Sure Chill Company, we launched a breakthrough technology in medical refrigeration last year. Our products have been received very well in the market and have been exported to 10 other countries. The
Medical Device ASIA | July-August 2016 | 43
insights we gained in the last one year have helped us develop an extended portfolio with 6 new offerings this year. We have been able to adapt the technology without diluting its core benefits to suit specific storage requirements of health centres and hospitals, including a more affordable Lite series for urban and semi urban health facilities with 50% cost reduction over last year and standalone storage devices that innovatively combine fridge and freezer for remote health centers, promising to reduce investments for government. All of this comes with the assurance of Godrej Smart care service which has the largest and the most extensive network in the country. We are sure that our new range will help the business grow manifold by increasing penetration. We are planning to build manufacturing capacity for 30,000 units from the current capacity of 10,000 units over the next 2 years and hope to generate Rs 200 crore revenue from medical refrigerator portfolio by 2020.”
About Godrej Appliances
The new product range includes three models in the Lite series- GVR 51 Lite, GVR 75 Lite and GVR 99 Lite with vaccine storage capacity of 51.5ltrs, 75.5ltrs and 99.5ltrs respectively. With hold-over time of approximately 4-5 days, 3 days and 1-2 days respectively, the models in the Lite series are lighter, slimmer and come at 50% reduced cost. They come with an externally readable data logger which records up to 30 days’ temperature reading and offers five customizable temperature alarm settings. The price range for the Lite series is Rs 70,000- Rs 90,000. The standalone fridge freezer combination- GVR 60 FF DC has a vaccine storage capacity of 67.5 ltrs and the GVR 225 AC has a capacity of 225 ltrs. In addition, Godrej Appliances has also introduced a new model to its blood bank refrigerator series- with an increased capacity of 225 ltrs. The price of this entire range varies from Rs. 1.5 L to Rs 5 L.
Sure Chill technology is based on the scientific principle that water is at its heaviest at 4°C, which happens also to be the ideal temperature for storing vaccines, fresh food and beverages. The technology harnesses this natural phenomenon to create a constantly chilled environment within the refrigeration unit - whether there is power or not. It is so reliable that it will maintain a completely steady temperature for 10 days or more after power has been interrupted. This is achieved through the movement of dense water at 4°C, generated as the system’s ice bank interacts with warmer water circulating within the unit. Once power has been used to generate the ice bank in the first instance, the Sure Chill technology channels the supply of naturally generated 4°C water to the refrigeration compartment without the need for any further power.
This is over and above the earlier range of Godrej Medical refrigerators with Sure Chill Technology with holdover period of 13 days. All products continue to guarantee never to freeze vaccines because of the patented Sure chill technology, limit temperature variation within the cabinet to less than 1 deg C, have a built-in intelligent temperature control and energy management system, minimize thermal shock, operate on only 2.5 hours/day power at 43 deg C ambient temperature and continue to be the world’s greenest ILRs. In terms of product offering, this portfolio is the best in the market today. 44 | July-August 2016 | Medical Device ASIA
The Godrej Group is one of the largest players in the Home Appliances space in India and has always delighted the consumer with relevant technology across a wide range of products. In 1958, Godrej was the First Indian Company to manufacture Refrigerators and has now become synonymous with the category. The company is known for delighting the consumer with innovative, relevant and green technologies. Godrej has created many milestones in the Indian appliance space – be it in the environment/energy efficiency space, including the launch of the first green AC in the world (2012), launch of the first green refrigerator in India (2001), launch of the first 5 star range of refrigerators (2008), launch of the first inverter AC in India (2005), the first refrigerator with 6 Star Performance(2012) or a pure consumer delight space like the launch of the music refrigerator, DAC (Dynamic Aqua Power Control) Technology, Tilt drum and U-Sonic technology in washing machine or Steam Microwave Ovens and Pizza/Kebab makers in Microwave Ovens. In recognition for its efforts, the brand has been conferred with many prestigious awards and honors such as the Consumer Superbrand Award (2011-12, 2013-14), ‘Voice of Consumer’ Award by Frost and Sullivan (2013, 2014), Business Superbrand (2008, 2010, 2011), ET Best Brands (2013-14), ET Promising Brand (2014-15); Consumer Superbrand (2009-10), ‘Most Innovative Company’ by Business Standard (2010), India Design Mark award for Green Balance ACs (2013) and many more. Both the manufacturing units of Godrej Appliances’ - in Shirwal and Mohali became the first and only manufacturing units in the country to be honored with the coveted Platinum Green Co certification for their efforts in green manufacturing. Godrej’s focus on balancing consumer needs with the environmental cause has enabled the organization to redefine the technology landscape in the appliances industry – to the delight of both the consumer and the environment. About Sure Chill The Sure Chill Company has developed a completely new approach to refrigeration that radically improves performance and can operate without constant power for days and weeks.
This process can continue until the ice bank, the ultimate generator of the dense water, finally melts and needs to be refrozen, which can take as little as two hours. In effect, the Sure Chill system creates a natural and internal energy store that is capable of providing a perfect, constantly chilled storage environment in areas where there is an intermittent power supply. And if there is no power at all, as if often the case in regions where vaccines are most needed, then the system can be teamed with solar power with exactly the same results. Vaccines are temperature-sensitive and must be stored at the correct temperature. They are irreversibly damaged by exposure to heat or freezing within the cold chain delivery system and once damaged they are less effective and do not protect fully from disease. Some reports say that this occurs in over 70% of vaccine shipments worldwide. Sure Chill’s technology solves this problem by providing constant reliable cooling without the need for continuous power. It is already saving lives. The Sure Chill Company, based in Snowdonia, Wales, has attracted support from the Bill and Melinda Gates Foundation and the Welsh Government and this helps in the development of new applications of the innovative technology. This technology is recognized by numerous international agencies including UNICEF, the World Health Organization (WHO) and the Global Alliance for Vaccines and Immunization (GAVI). The Sure Chill technology is patent granted in the UK and filings have been placed and are now granting in 88 additional countries worldwide. The Company was formed in February 2003. The Chairman and major investor is UK Business Angel of the Year, Peter Saunders OBE.
Curofy builds its own Medical device marketplace
C
PROFILE: Curofy
urofy has always been at the forefront of innovations as far as easing the daily struggles of the doctors is concerned. It also opens up an array of opportunities for the industry stakeholders to reach their target audience in the most frugal manner. Curofy has been constantly improving its platform for the doctors. However after much deliberation, they are finally venturing towards the industry with the launch of Medical Device Marketplace. Curofy for devices allows distributors and manufacturers to connect directly with the doctors and fulfill orders. The process is very easy to comprehend. The doctors can send queries via Curofy app, the distributors can then bid for the query. The doctors have the power of accepting or rejecting the bid as per their choice. On acceptance of a bid, the seller is charged a nominal amount for the successful lead, and the contact details of the user are forwarded to the seller. The platform is surely a boon for the doctors who are plying their trade in tier 2 and tier 3 cities. This is Curofy’s second web product besides their recruitment platform that was launched a few days ago. With this, Curofy is moving one step ahead to engage directly with the industry and is very much in line with the mission of making lives of the doctors easier and more efficient. It is indeed true that healthcare delivery today, is still geographically biased with the metros and tier 1 cities taking the majority of the share. There is not only dearth in the number of trained personnel but also the absence of modern facilities has put a huge dent in the healthcare system in the smaller towns and rural areas. Hence this new platform. Curofy is launching the platform for medical device industry at Medicall 2016, India’s premier B2B medical equipment show, hoping to make early inroads in the industry. “Think of a day when you can get the best treatment at the Sonipats, the Shamlis and the Midnapores of the country” Says Pawan Gupta, cofounder of Curofy. If Curofy can achieve what they are promising, they can truly disrupt the healthcare space in the country. And who knows, maybe even worldwide.
Curofy is India’s largest community of verified doctors. Curofy offers doctors a spam-free and secure environment to communicate with each other. Doctors can provide referrals, share cases, call other doctors without saving numbers and have access to most recent, specialty-wise developments taking place in their field. Curofy, through its relevance based algorithm, ensures that doctors get the most relevant case discussions and news updates on their mobile app and ultimately leading to a very high engagement within the community. More than 250 cases across 25 specialties are discussed every day. Curofy is soon moving from 25 specialties to 400 sub specialties to provide even more relevant news updates and cases for discussions to its doctors’ community and thus, ensuring even higher engagement in future. Within eleven months of its launch, more than 50,000 doctors from across 300 cities are using this app. Curofy got funded, in a dramatic, reality television-type formatted live event on CNBC called TiE the Knot at TiEcon 2014, a conference organized by The Indus Entrepreneurs in October. Some highly respected angels like Rajul Garg (Sunstone Business School, Global Logic, Pine Labs), Alok Mittal (JobsAhead, Canaan), India Quotient, Spice Labs, Dinesh Agarwal (Indiamart), Dr Shuchin Bajaj (Cygnus Hospitals), and Presha Paragash (Zostel, Sol Primero) have invested in the company.
Curofy gets almost 700 signups every day and almost 250 case discussions which translates to 1 doctor signing up every 2 minutes on its mobile app each day. More than 1,00,000 doctors are currently registered on the app spending 30,00,000 minutes every month. Medical Device ASIA | July-August 2016 | 45
Intertek approved as India’s first Certification Body for the ICMED scheme
(Indian Certification for Medical Devices)
Pelican BioThermal Announces Asia Expansion with Additional Distribution Partners Pelican BioThermal, a global leader providing the largest range of innovative temperature-controlled packaging solutions serving the life sciences industry, has expanded its operations in Asia with the launch of a new network of distribution partners in the region.
Intertek, a leading Total Quality Assurance provider to industries worldwide, today announced another significant milestone by being approved as India’s first certification body for the ICMED scheme (Indian Certification for Medical Devices). This quality certification scheme for medical devices is an initiative by the Association of Indian Medical Device Industry (AIMED) in collaboration with the Quality Council of India (QCI) and the National Accreditation Board for Certification Bodies (NABCB) in quality certification for medical devices in the country. Through the introduction of this quality certification scheme, the associations intend to enhance patient safety, and increase consumer protection along with providing much needed product credentials to manufacturers to instil confidence among buyers. The scheme is also intended to significantly eliminate trading of sub-standard products or devices where supply chains are unknown, a widespread and injurious occurrence in the Indian market. Mr. Sandeep Vig, Director of Business Assurance and Electrical for Intertek India said, “We are extremely thankful to AIMED, QCI and NABCB for providing us with an opportunity to showcase our expertise in quality testing for the medical device industry. With this accreditation, we will aim to reduce the substantial cost and time for Indian companies to obtain globally accepted quality certification and thus eliminate the malpractice of sub-standard or fraudulent certification and quality audits.” “QCI is initiating a number of voluntary certification schemes to facilitate industry and demonstrate compliance to the best global standards of which ICMED is one of them. NABCB is committed to providing world class accreditation services in support of these schemes and having one of the most well-known certification bodies approved under the ICMED scheme adds value to the Scheme.” said Anil Jauhri, CEO, NABCB.
Pelican BioThermal announced it has joined forces with the region’s distinguished distributors, Pharmaserv Express of the Philippines and CMC Element of China, to further enhance its operations offering in Asia. Pharmaserv Express works closely with national health services to skillfully transport pharmaceutical products throughout the complex geography of the Philippines. CMC Element distributes a variety of health care products, including pharmaceuticals protected in temperature controlled packaging, across the vast Chinese market using their extensive network. The latest development demonstrates Pelican BioThermal’s continued growth in Asia and follows the company’s recent launch of its new operational facility in Singapore. The new industry partnerships with these key distributors signals another major development in Pelican BioThermal’s expanding presence and support network in Asia, further enhancing the extending range of products and services offered by the company in the region. In particular, the new distributors enhance customer support for global customers shared with Pelican BioThermal, by offering local hours, local language and local service and inventory at the point of final distribution of pharmaceuticals. Pelican BioThermal’s growing global network supports customers wherever they are located and establishing productive partnerships with reliable, reputable, dedicated distributors further strengthens the Asia based business offering. The increasing network of distribution partners complements the company’s newly established Asia headquarters, which is co-located with Pelican BioThermal’s authorized distributor for Singapore, Enviropac. Benson Teo, Pelican BioThermal’s Senior Director of Sales for Asia, said: “We are delighted to announce the latest additions to our expanding network of dedicated distributors. We welcome Pharmaserv Express and CMC Element to our Asia operations; these well-established partners will play a pivotal part in our expansion efforts in Asia.
Intertek’s full suite of medical quality and compliance solutions include: Regulatory Requirements for Medical Equipment, Medical Product Testing Solutions and Medical Management Systems Certification & Auditing.
“As the global cold chain logistics industry continues to thrive we want to further demonstrate we have the critical capabilities to support the growing Asia pharma marketplace.”
About Intertek Intertek is a leading Total Quality Assurance provider to industries worldwide. Our network of more than 1,000 laboratories and offices and over 40,000 people in more than 100 countries, delivers innovative and bespoke Assurance, Testing, Inspection and Certification solutions for our customers’ operations and supply chains. Visit www.intertek.com.
The region continues to be an area of pronounced growth for Pelican BioThermal and forging links with these well-established distribution partners will increase the company’s global reach and support network for customers.
46 | July-August 2016 | Medical Device ASIA
Visit http://PelicanBioThermal.com to learn more about Pelican BioThermal’s wide range of reusable thermal shippers, services and asset management solutions.
International Medical Group
EHIC in the Wake of Brexit: What’s Next for UK Travellers and Expats? The European Health Insurance Card (EHIC) has long been taken for granted by many UK citizens, who have enjoyed access to reduced-cost — and sometimes free — state health care when travelling in the European Economic Area (EEA) and Switzerland. Now, after the UK’s vote in June to leave the EU, the future of the EHIC is up in the air, which could leave UK travellers and expats without the proper cover. So what’s next? International Medical Group (IMG) experts Philip Wright and Geoff Tothill weigh in on misconceptions about the EHIC, what UK travellers and expats need to know, and the advantages of travel medical insurance and international private medical insurance (iPMI) — viable alternatives to the state-funded cover. “Prior to the vote, a lot of people didn’t realise that even with the EHIC, they may still have medical bills for care they receive outside of the UK,” says Wright, managing director of IMG’s European division. “On the government-issued card, it says, ‘Make sure you have valid travel insurance.’ It’s printed very clearly that the EHIC may not cover the full cost of treatment abroad.” For expats, the problem is even bigger. Prior to the vote to leave the EU, UK citizens who worked or lived outside of the EEA on a permanent basis were not entitled to receive medical treatment under the National Health Service (NHS), and most were not entitled to use the EHIC to access care abroad. This means that even before “Brexit,” some UK expats needed to find alternative international health cover. Misunderstandings about the benefits the EHIC provides continue to pose a problem for travellers and expats, and will remain an issue if the UK — like Switzerland — decides to use the EHIC even when it is no longer a member of the EU. “With the EHIC, people have become used to travelling in Europe with some level of comfort about what medical cover they have,” Wright says. “Because the card is free and government-funded, they don’t often consider other forms of international health cover. However, without the EHIC, I’m worried that some people could have large medical bills they’ll struggle to pay, unless the UK makes another provision.” Tothill, IMG’s chief medical officer, says he suspects the UK will either continue using the EHIC or will develop another provision with member
states, similar to Switzerland’s arrangement. “I can’t imagine England opting out of reciprocal health care agreements,” Tothill says. “There are lots of things in Europe that have to function as a group, and health care is one of them.” Regardless of the outcome of UK negotiations surrounding the EHIC, people can’t continue to bury their heads in the sand when it comes to their health care, Wright says. Now more than ever, it’s important for travellers and expats to understand the benefits the EHIC provides, and the gaps in cover it leaves. “People often travel with EHIC cover, but they’re not aware of its limitations,” Tothill says. “It’s designed to simply cover the costs of emergency treatment — not to provide ancillary services or cover for routine medical care, elective procedures, medical evacuations, medical repatriation or patient transfers.” Travel medical insurance and iPMI, on the other hand, fill the gaps in cover left by the EHIC, and can serve as viable alternatives for UK travellers and expats. The chief advantage of a travel medical or iPMI plan is that the policyholder can often seek treatment wherever is most convenient for
them, including at private and state facilities. Most iPMI providers don’t force the patient to receive care at an EHIC-qualifying hospital. In some cases, this could mean the patient receiving better care at a higherquality facility. For expats, one added benefit of iPMI is especially important: stability. “iPMI provides a stable, consistent platform for delivering health care around the world. With a long-term iPMI policy, there’s consistency in what’s delivered to the client and when and how, whereas there’s much more variation in the delivery of benefits under the EHIC, which is subject to a lot of economic pressures,” Tothill says. “iPMI provides expats comfort knowing that their health care will remain the same well into the future.” Although we’re years away from any decision about the use of the EHIC in the UK, it’s important for travellers and expats to be aware of the misconceptions surrounding the EHIC and the alternative forms of cover available. “If you have access to the EHIC, then you should make sure you’re enrolled and have the card, because there are times when it can be useful. However, it’s important to stress that the EHIC provides only a small part of the more comprehensive cover that can be provided by travel medical insurance or iPMI,” Tothill says.
Medical Device ASIA | July-August 2016 | 47
Energy saving with KRELUS IR-Heaters
Milacron Launches “eSTORE” to Serve Customers 24/7/365!
M
ilacron Holdings Corp. (NYSE: MCRN), a leading industrial technology company serving the plastics processing industry, have announced that their new Milacron eSTORE is NOW live and fulfilling customers orders in North America and Europe. Milacron’s industry leading product brands have had separate ecommerce operations in the past but this marks the launch of a streamlined eSTORE representing Milacron and Ferromatik branded injection machines, Milacron extrusion machines, Mold-Masters hot runners and control systems as well as DME’s vast catalog of mold components and MRO industrial supplies.
Fotr more than 40 years, KRELUS have been specialists for Infraredheaters.
the product surface and they can be switched instantly ON and OFF even for short production breaks.
With the emphasis on the special high performance IR-heaters based on an innovative technology, KRELUS customers have a competent partner for both standard and custom made heating solutions. Alongside many more applications some of the interesting areas are:
Most products (thermoplastics/ paper/textiles) absorb heat energy in the medium wave range
• Heating of composite materials from carbon-/glass-/natural-fibres containing a matrix of PP/PA/PEEK/ etc. • Embossing of PVC/PA/etc. • Thermoforming • Coating of paper, foils, metals, films and textiles • Lamination of a wide variety of materials • Pre-drying and heating equipment etc. The superior, innovative KRELUS technology applies direct radiation heat from its resistance source to the product (without any glass quartz or ceramics). High thermal insulation materials prevent heat loss from the reverse side of the heaters. The very rapid response time of the KRELUS medium-wave IR-heaters allows operations with precise temperature control on
(± 3,0 μm) extremely well. The emission range of the KRELUS-IR is perfectly matched to these absorption ranges. This fact leads to a higher efficiency and consequently to cost savings in comparison to traditional standard heaters. KRELUS IR-heaters are available in standard modules in a variety of sizes and capacities. Custom made solutions are available up to approximately 8,000 mm in a single piece. The modular sizes facilitates individual control zones of various dimensions or to manage uniform temperature profiles in continuous processes. We shall be pleased to welcome you at our booth at K’2016: Hall 03, Stand 3E34 KRELUS AG, Ausserfeldstrasse 14, CH-5036 Oberentfelden, Tel. ++41 62 739 3070, Fax ++41 62 739 3089, E-Mail: krelus@krelus.ch, http:// www.krelus.ch
48 | July-August 2016 | Medical Device ASIA
“We are thrilled to launch the new Milacron eSTORE to our valued customers,” said Tom Goeke, Milacron Chief Executive Officer. “This significant milestone will allow our customers to have 24 hour access to spare parts, systems, components and industrial supplies they demand, all from Milacron’s industry leading product brands, via their computers, smart phones, and tablets from anywhere in the world. It furthers our commitment to our customers enabling them to perform modular purchases from our specific product brands or cross shop throughout our entire product portfolio.” The eSTORE is Windows, Mac and iOS friendly, and features an intuitive and familiar online shopping experience and a simplified registration process. Milacron’s eSTORE is enabled with the latest security programs to ensure secure and safe transactions, including rapid credit card processing. Tony Galuardi, Vice President and General Manager of Milacron Aftermarket stated, “The Milacron eSTORE is another way Milacron is committed to serving our customers better every day.” Galuardi continued, “We’ve developed a comprehensive ecommerce site that allows you to track your order history to ensure reordering those frequent items will be quick and easy and our injection machine customers will be able to search by machine to order parts through our interactive catalog.” DME President Peter Smith said, “This eSTORE platform is key to linking customers to DME’s vast product inventory. The mold base configurator provides our customers in the Americas and in Europe the opportunity to design custom mold bases that meet their design requirements, providing immediate design and CAD feedback and pricing. The eSTORE will also act as our source for standard MRO components, providing customers instant access to our inventory of over 10,000 in stock parts.” Since the soft launch of the site in May of this year, 1000’s of customers have processed orders. Milacron will be using the site to launch new products to customers and promote seasonal savings and quick delivery options. The sites functionality is expanding this Summer to include an intuitive Hot Runner Configuration tool for our Mold-Masters product brand. Whether you’re at your desk, on the shop floor, or on the road, the eSTORE will help our customers shape or reshape the future of their businesses at the click of a button or the touch of a screen.
Agilent Technologies Introduces
InfinityLab Liquid Chromatography Instruments, Columns & Supplies • Allow tracking of critical method information for high data confidence • Also Showcases New 1260 Infinity II LC System “The 1260 Infinity II LC system as the new core platform of the InfinityLab LC Series represents a considerable technology refresh to increase customer’s efficiency in three ways: delivering ted analytical data, outstanding usability, and easy integration into existing lab environments,” said Helmut SchulenbergSchell, Director, Business Development – Liquid Phase Analysis. “The InfinityLab columns and supplies are designed to fit perfectly with our new InfinityLab LC Series,” said Martin Greiner, senior Product Manager. “These products are designed to improve overall usability and reduce laboratory operating costs.”
Agilent Technologies introduces InfinityLab, a product family of liquid chromatography instruments, columns and supplies. A key element of this introduction is the new Agilent 1260 Infinity II liquid chromatography system, which will bring high-end technology from Agilent’s flagship 1290 Infinity II LC into the company’s core platform.
T
he Agilent 1220 Infinity II LC (available in August), 1260 Infinity II LC (announced today), together with the current 1290 Infinity II LC systems create the new InfinityLab LC Series. The InfinityLab columns and supplies announced today allow tracking of critical method information for high data confidence and offer ergonomic designs for exceptional system usability.
“We are looking at partnering with labs for their entire workflow, providing solutions at each step of the way, whether it is the instruments, consumables or the software they need in order to help them resolve complex scientific challenges,” said Bharat Bhardwaj, Country Manager, Agilent India. “The 1260 Infinity LC II introduced today, along with the existing 1290 Infinity II LC and soon-to-be launched 1220 Infinity II LC create our new InfinityLab LC Series, which effectively address all laboratory needs. With the addition of these products, Agilent is now adding a renewed focus on the customer, which is responsible for our success globally and in India. The customer now sees and experiences
one face from Agilent irrespective of their needs and requirements. This is a big move away from when the same customer was visited by product managers of multiple product lines, service & sales, and technical support people,” Bhardwaj adds. “This streamlines the customer’s interaction with Agilent, and positively impacts his up-time, enabling him to provide better solutions and results to his customers. This is our new mantra at Agilent: putting the customer first.” For more information, visit www.agilent.com/chem/infinitylab and www.EfficientUHPLC.agilent. com/1260
About Agilent Technologies Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenue of $4.04 billion in fiscal 2015 and employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com
Medical Device ASIA | July-August 2016 | 49
Latest Medical Devices 2016 Anesthesia Machine A5 Anesthesia System from Mindray The new A5’s intuitive user interface and ergonomic design simplifies workflows. The 15" touch-screen enables clinicians to easily select ventilation settings, so less time is spent maneuvering and more time is devoted to patient care. The central brake and integrated cable sweeps enhance device mobility.
Aspirators PM60 EasyVac Aspirator from Precision Medical The PM60 EasyVac Aspirator has a high performance 1/5 horsepower pump that delivers 0-26 inHg (0-660 mmHg) among the highest in the industry.
Angiography Systems BRANSIST Safire VB9 Slender Angiography System from Shimadzu Shimadzu, a pioneer in angiography systems using directconversion FPDs, has developed a big-plane system that produces even higher quality images and ensures interventional procedures are safe and smooth.
Apheresis Machine COBE Spectra Apheresis System from Terumo BCT Terumo BCT's industry-leading therapeutic apheresis technology, the COBE Spectra Apheresis System, uses a single platform for customized patient procedures that match treatment objectives. These wide-ranging procedures are designed for operator ease of use and control over desired outcome.
36 Device 50 | July-August | Medical Device ASIA ASIA July-August2016 2016 | Medical
Atomic Absorption Spectrometers TRACE 1300 Atomic Absorption Spectrometer from Aurora Current industry demands require that elemental analyses embody higher precision, higher sensitivity, and lower detection limits than ever before. Aurora has built a reputation as an industry leader in atomic absorption and atomic fluorescence spectrometry. Building on this success, Aurora is pleased to introduce their newest addition to their line of atomic absorption spectrometers - the TRACE 1300.
Latest Medical Devices 2016 Audiometers MADSEN Xeta Clinical Audiometer from Otometrics The MADSEN Xeta audiometer offers today’s most requested features including portability, efficiency, speed, flexible settings and intuitive use.
Autoclaves Elara 6 Class B Dental Autoclave from Tuttnauer Compact and versatile, the Elara 6 is the ideal sterilization solution for any medical, dental or healthcare environment where speed and flexibility are required without compromising quality.
Blood Coagulometers Coa Data 2001 Blood Coagulometer from Dutch Diagnostics Coa Data 2001 is a 2 channel coagulation analyzer for all clotting assays. It is economic, semi automated coagulation analyzer for routine laboratories and back up for automated analyzers.
Benchtop Sterlizers STERILCLAVE® 6 B SPEEDY Benchtop Sterilizer from Cominox Solid, hollow, porous, wrapped or not: all the instruments and materials in a medical, dental or health environment can be sterilized with this process, that guarantees the quality of the sterilization on the most different types of instruments and in the most complex situations. With the compactness and speed of SterilClave 6 B SPEEDY, for greater ?exibility and ef?ciency.
Birthing Pools Eco Birth Pool in Box from NCT Birth Pool is available in two sizes, Regular or Mini. Regular size pool is recommended for mothers over 5’ 6” tall, and includes an internal seat and top handles. Mini birth pool is recommended for rooms smaller than 3 x 2.7 metres, and includes top handles.
Blood Gas Analyzers b 221 Blood Gas System from Cobas In critical-care testing every minute counts. The cobas b 221 system offers fast determination of 17 of the most important critical-care blood parameters. The cobas b 221 system is a multiparameter analyser for blood gas, electrolytes, COoximetry and metabolites providing comprehensive information in critical-care testing.
Medical Device ASIA 37 Medical Device ASIA | July-August2016 2016 | 51 | July-August
Latest Medical Devices 2016 Blood Pressure Monitors Wrist Blood Pressure Monitor with A.P.S.ÂŽ HEM-650 from Omron Omron's Advanced Positioning Sensor automatically confirms the monitor is at heart level, ensuring an accurate reading.
Cell Analysis Systems BioFlux 1000/1000Z Cell Analyzers from Fluxion
Blot Analysis Equipment
The BioFlux 1000 and 1000Z systems offer a fully-integrated solution for automated, high throughput shear flow assays. High performance microscopy components are seamlessly integrated with BioFlux controls to offer the ultimate in speed, precision and convenience.
FluorChem E and M Blot Analyzer from ProteinSimple FluorChem E’s innovative compact design incorporates state-of-the-art CCD optical technology with simplified touch screen control for effortless detection of chemiluminescent, colorimetric and UV fluorescent gels and blots.
Bronchoscopes BF-1T180 Video Bronchoscope from Olympus Olympus BF-1T180 bronchoscope with a generous 3.0mm channel diameter may improve the functionality in the procedure room. The BF-1T180 is part of the EVIS EXERA II platform which enhances visualization of the capillary network and mucosal surfaces.
Cell Counters Luna Automated Cell Counter from Logos Biosystems The Luna automated cell counter is a small, fast, and affordable image-based cell counting device that automatically counts various kinds of cells for research use. The Luna automated cell counter helps measure the number, as well as viability of cells (live, dead, total cells) with sophisticated optical components and advanced image analysis algorithms.
Calorimeters WPA CO7500 Colorimeter from Biochrom The Biochrom WPA CO7500 colorimeter is a value for money instrument that has been designed for use in educational establishments such as schools and colleges. It is compact, lightweight and ergonomically designed to withstand student use! This makes it ideal for use in busy teaching laboratories.
38 Device 52 | July-August | Medical Device ASIA ASIA July-August2016 2016 | Medical
Colorimeters DR/890 Portable Colorimeter from Hach DR/800 Portable Colorimeter Series are durable, hand-held, filter photometers which are designed specifically for the rigors of on-site testing, with rugged components and waterproof, dustproof, chemical-resistant housings.
Latest Medical Devices 2016 Colposcopes
CT Scanners
Model 1DW-LED Colposcope from Leisegang
LightSpeed VCT CT Scanner from GE Healthcare
Model 1DW-LED comes with a drum changer with a magnification of 7.5 / 15 / 30, a convenient angular insight of 45° and it is equipped with an extremely bright LED lighting.
The LightSpeed VCT is the latest innovation in CT technology. VCT means "Volume CT"...ushering in a new era in CT imaging.
Defibrillators Confocal Microscopes TCS LSI Confocal Microscope from Leica The Leica TCS LSI macro confocal is the first super zoom confocal that offers high resolution plus a large 16mm field of view for in vivo imaging.
Conventional Laryngoscopes McCoy Range Laryngoscope from Penlon
Defibtech Automatic External Defibrillator Defibtech introduces the newest generation Automatic External Defibrillator (AED). Now there is something you can do to improve the odds dramatically with a solution that is both easy to use and extremely affordable.ilable.
Dental Sterilization EVB and EVS Classical Class B/S Autoclave from Tuttnauer
McCoy Range Laryngoscope is a world leader for difficult intubation. Over ten years of refinement and experience guarantees performance that can be trusted.
The EVB and EVS are pre & post vacuum sterilizers built for dental and private clinics that wish to upgrade to an autoclave that uses vacuum air-removal. The EVB and EVS are the classic and reliable choice, offering advanced technology at an affordable price.
Cryosurgery Devices
Dialysis Machines
Leisegang LM-900 Cryosurgical System from Cooper Surgical
DBB-06 Dialysis System from Nikkiso
The Leisegang LM-900 Cryosurgery System is the right unit for a busy practice. The calibrated, easy-to-read pressure guage helps reduce the number of repeat procedures, and the solid brass gas manifold offers added safety.
Nikkiso’s premier dialysis system in the US, the DBB-06 delivers an enhanced ability to consistently improve both patient outcomes and clinical efficiency.
Medical Device ASIA 39 Medical Device ASIA | July-August2016 2016 | 53 | July-August
Suffering from a Heart Condition, but Safe at Home Telemedicine Prevents Death and Hospital Stays
T
elemedicine could save hundreds of heart patients from a hospital stay each day. Studies show that digital, around-the-clock care can greatly improve life expectancy and quality of life. Experts see telecardiology as a promising early-warning system to improve the quality of care in heart patients – particularly in rural regions. How digital applications will characterize the future of cardiology is discussed by experts at the MEDICA EDUCATION CONFERENCE 2016 in Düsseldorf, on November 16.
of the pulmonary arteries in the lung circulation of the patient.
Approximately 1,200,000 people in Germany are suffering from heart failure. With around 1,000 in-patient admissions per day, this disease is the most common reason for hospital stays. “Many chronic diseases deteriorate without noticeable symptoms presenting, until suddenly an emergency situation develops”, says Professor Dr. med. Friedrich Köhler, Head of the Centre for Cardiovascular Telemedicine at the Berlin Charité hospital. In most cases, these deteriorations can be measured before reaching this stage.
Patient’s treatment could be improved, particularly in rural regions where a trip to the cardiologist often means a long journey. The aim of telemedicine is not to replace doctor’s visits, emphasizes Köhler: “A sole telemedical care is not allowed in Germany and would be undesirable from a medical point of view.”
This also applies to heart failure: By using telecardiology, says Köhler, we can observe disease progression and intervene at an early stage in the case of conspicuous values. To this end, patients under telemedical care either receive measuring devices for their homes (e.g. tele-scales and tele-ECG), or data from pre-existing telemedical therapeutic implants (e.g. implanted defibrillators) can be used for therapy management.
What kinds of telemedical methods are available for people with heart diseases, and how physicians can use them successfully, is discussed by experts at the MEDICA EDUCATION CONFERENCE 2016 in Düsseldorf on 16 November. On this day, the focus will be on the topic “Internal Medicine: Future Technologies and Remote Patient Management”. The MEDICA EDUCATION CONFERENCE is an interdisciplinary advanced training course of the German Society for Internal Medicine (DGIM) and the Messe Düsseldorf based on the motto “Science Meets Medical Technology” that is taking place from November 14 to 17, 2016 in Düsseldorf.
New developments include diagnostic implants specifically developed for telemedical therapy management, which can, for example, measure the pressure 54 | July-August 2016 | Medical Device ASIA
Based on these values, a cardiologist can, if necessary, individually adjust drug dosage, ask the patient to come in for a consultation, or order an immediate hospitalization. “Thanks to this digital early warning system, we can care for heart patients around the clock and spare them from unnecessary doctor’s visits or even hospital stays,” says Köhler.
The fact, that telecardiology can increase life expectancy and quality of life was shown by two large clinical trials. Thus, in the CHAMPION study heart values of the participants were determined via telecardiology on a daily basis and the drug dose was adjusted accordingly. The number of hospitalizations amongst these patients was reduced by one third. In the IN-TIME study physicians used telecardiology to treat heart patients with an implanted defibrillator: the participants had a significantly lower risk of death than patients without remote aftercare.
Government of India, Registrar of Newspapers of India (RNI)#: DELENG/2009/30008